0001437749-22-012372.txt : 20220513 0001437749-22-012372.hdr.sgml : 20220513 20220513163140 ACCESSION NUMBER: 0001437749-22-012372 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220513 DATE AS OF CHANGE: 20220513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Genprex, Inc. CENTRAL INDEX KEY: 0001595248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900772347 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38244 FILM NUMBER: 22923300 BUSINESS ADDRESS: STREET 1: 1601 TRINITY STREET, BLDG. B STREET 2: SUITE 3.322 CITY: AUSTIN STATE: TX ZIP: 78712 BUSINESS PHONE: 512-537-7997 MAIL ADDRESS: STREET 1: 1601 TRINITY STREET, BLDG. B STREET 2: SUITE 3.322 CITY: AUSTIN STATE: TX ZIP: 78712 10-Q 1 gnpx20220331_10q.htm FORM 10-Q gnpx20220331_10q.htm
0001595248 Genprex, Inc. false --12-31 Q1 2022 0.01 0.01 10,000,000 10,000,000 0 0 0 0 0.001 0.001 200,000,000 200,000,000 47,879,708 47,879,708 47,874,708 47,874,708 3 5 0 0 0 0 0 10 10 00015952482022-01-012022-03-31 xbrli:shares 00015952482022-05-10 thunderdome:item iso4217:USD 00015952482022-03-31 00015952482021-12-31 iso4217:USDxbrli:shares 00015952482021-01-012021-03-31 0001595248us-gaap:CommonStockMember2020-12-31 0001595248us-gaap:AdditionalPaidInCapitalMember2020-12-31 0001595248us-gaap:RetainedEarningsMember2020-12-31 00015952482020-12-31 0001595248us-gaap:CommonStockMember2021-01-012021-03-31 0001595248us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-31 0001595248us-gaap:RetainedEarningsMember2021-01-012021-03-31 0001595248us-gaap:CommonStockMember2021-03-31 0001595248us-gaap:AdditionalPaidInCapitalMember2021-03-31 0001595248us-gaap:RetainedEarningsMember2021-03-31 00015952482021-03-31 0001595248us-gaap:CommonStockMember2021-12-31 0001595248us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001595248us-gaap:RetainedEarningsMember2021-12-31 0001595248us-gaap:CommonStockMember2022-01-012022-03-31 0001595248us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-31 0001595248us-gaap:RetainedEarningsMember2022-01-012022-03-31 0001595248us-gaap:CommonStockMember2022-03-31 0001595248us-gaap:AdditionalPaidInCapitalMember2022-03-31 0001595248us-gaap:RetainedEarningsMember2022-03-31 00015952482018-03-31 utr:Y 0001595248srt:MinimumMember2022-01-012022-03-31 0001595248srt:MaximumMember2022-01-012022-03-31 00015952482021-01-012021-12-31 0001595248gnpx:InvestorsMembergnpx:RegisteredDirectOfferingMember2021-02-102021-02-10 0001595248gnpx:InvestorsMembergnpx:RegisteredDirectOfferingMember2021-02-10 00015952482018-04-03 0001595248us-gaap:WarrantMember2022-01-012022-03-31 0001595248gnpx:BearCreekCapitalWarrantOneMember2021-12-31 0001595248gnpx:BearCreekCapitalWarrantTwoMember2021-12-31 0001595248gnpx:BearCreekCapitalWarrantsMember2021-01-012021-12-31 0001595248gnpx:WarrantsIssuedForServicesMembergnpx:FundathenaIncMember2018-01-29 0001595248gnpx:WarrantsIssuedForServicesMembergnpx:FundathenaIncMember2022-01-012022-03-31 0001595248gnpx:The2018EquityIncentivePlanMember2018-04-03 0001595248gnpx:The2009PlanMember2018-04-03 xbrli:pure 0001595248gnpx:The2018EquityIncentivePlanMember2021-01-012021-01-01 0001595248gnpx:The2018EquityIncentivePlanMember2022-01-012022-01-01 0001595248gnpx:The2018EquityIncentivePlanMember2022-03-31 0001595248gnpx:The2018EmployeeStockPurchasePlanMember2018-04-03 utr:M 0001595248srt:MinimumMember2022-03-31 0001595248srt:MaximumMember2022-03-31 0001595248srt:MinimumMember2021-01-012021-12-31 0001595248srt:MaximumMember2021-01-012021-12-31 0001595248srt:MinimumMember2021-12-31 0001595248srt:MaximumMember2021-12-31 0001595248us-gaap:EmployeeStockOptionMember2022-01-012022-03-31 0001595248us-gaap:EmployeeStockOptionMember2022-03-31 0001595248us-gaap:PerformanceSharesMember2022-03-31 0001595248gnpx:PerformancebasedWarrantMember2022-03-31 0001595248gnpx:MdAndersonMembergnpx:ClinicalTrialAgreementMember2018-07-012018-12-31 0001595248gnpx:MdAndersonMembergnpx:ResearchAgreementMember2018-07-012018-07-31 0001595248gnpx:NationalInstituteOfHealthMember2009-12-31 0001595248gnpx:NationalInstituteOfHealthMember2009-01-012009-12-31 0001595248us-gaap:LicenseAgreementTermsMember2021-03-03 0001595248gnpx:NationalInstituteOfHealthMember2016-12-31 0001595248gnpx:NationalInstituteOfHealthMember2016-10-012016-12-31 0001595248gnpx:NationalInstituteOfHealthMember2016-01-012016-12-31 0001595248gnpx:NationalInstituteOfHealthMember2017-01-012017-03-31 0001595248gnpx:NationalInstituteOfHealthMember2017-03-31 0001595248gnpx:NationalInstituteOfHealthMember2017-04-012017-06-30 0001595248gnpx:UniversityOfPittsburghMembergnpx:LicenseAgreementMember2020-02-11 0001595248gnpx:UniversityOfPittsburghMembersrt:MinimumMembergnpx:LicenseAgreementMember2020-02-11 0001595248gnpx:UniversityOfPittsburghMembersrt:MaximumMembergnpx:LicenseAgreementMember2020-02-11 0001595248gnpx:UniversityOfPittsburghMembergnpx:DosingOfFirstHumanPatientInAPhaseIClinicalTrialMembergnpx:LicenseAgreementMember2020-02-11 0001595248us-gaap:SubsequentEventMember2022-04-012022-04-01 0001595248gnpx:The2018EquityIncentivePlanMemberus-gaap:SubsequentEventMember2022-04-182022-04-18 0001595248us-gaap:SubsequentEventMember2022-05-042022-05-04
 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549  

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________________ to ______________

 

Commission file number: 001-38244

 

GENPREX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

90-0772347

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

 

 

3300 Bee Cave Road, #650-227, Austin, TX

78746

(Address of principal executive offices)

(Zip Code)

 

(512) 537-7997

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

GNPX

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No ☒    

 

As of May 10, 2022, the registrant had 47,898,351 shares of common stock, par value $0.001 per share, outstanding.

 


 

 

 

 

 
 

GENPREX, INC.

TABLE OF CONTENTS

 

 

 

 

 

Page No.

 

 

 

 

 

PART I

 

FINANCIAL INFORMATION

 

3

 

 

 

 

 

ITEM 1.

 

FINANCIAL STATEMENTS

 

3

 

 

Condensed Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021

 

3

 

 

Condensed Statements of Operations for the Three Months Ended March 31, 2022, and 2021 (unaudited)

 

4

    Condensed Statements of Changes in Stockholders' Equity for the Three Months Ended March 31, 2022, and 2021 (unaudited)   5

 

 

Condensed Statements of Cash Flows for the Three Months Ended March 31, 2022, and 2021 (unaudited)

 

6

 

 

Notes to Unaudited Condensed Financial Statements

 

7

ITEM 2.

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

18

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK   24

ITEM 4.

 

CONTROLS AND PROCEDURES

 

24

 

 

 

 

 

PART II

 

OTHER INFORMATION

 

25

 

 

 

 

 

ITEM 1.

 

LEGAL PROCEEDINGS

 

25

ITEM 1A.

 

RISK FACTORS

 

25

ITEM 2.

 

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

25

ITEM 3.   DEFAULTS UPON SENIOR SECURITIES   25
ITEM 4.   MINE SAFETY DISCLOSURES   25

ITEM 5.

 

OTHER INFORMATION

 

25

ITEM 6.

 

EXHIBITS

 

25

SIGNATURES

27

 

2

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Genprex, Inc.

 

Condensed Balance Sheets (unaudited)

 

  

March 31,

  

December 31,

 
  

2022

  

2021

 

Assets

  (unaudited)     

Current assets:

        

Cash and cash equivalents

 $34,555,337  $38,628,876 

Accounts receivable

 $32,171    

Prepaid expenses and other

 $1,115,601  $511,348 

Total current assets

 $35,703,109  $39,140,224 

Property and equipment, net

 $41,878  $48,608 

Other assets:

        

Security deposits

 $10,000  $8,691 

Supplies

 $3,010,243  $3,022,403 

Intellectual property, net

 $644,201  $642,360 

Total other assets

 $3,664,444  $3,673,454 

Total assets

 $39,409,431  $42,862,286 

Liabilities and Stockholders’ Equity

        

Current liabilities:

        

Accounts payable

 $1,252,978  $973,195 

Other current liabilities

 $1,131,839  $612,100 

Total current liabilities

 $2,384,817  $1,585,295 

Stockholders’ equity:

        

Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding

      

Common stock $0.001 par value: 200,000,000 shares authorized; 47,879,708 and 47,874,708 shares issued and outstanding at March 31, 2022, and December 31, 2021, respectively

 $47,879  $47,874 

Additional paid-in capital

 $120,717,072  $119,246,970 

Accumulated deficit

 $(83,740,337) $(78,017,853)

Total stockholders’ equity

 $37,024,614  $41,276,991 

Total liabilities and stockholders’ equity

 $39,409,431  $42,862,286 

 

See accompanying notes to the unaudited condensed financial statements.

 

3

 

 

 

Genprex, Inc.

 

Condensed Statements of Operations (unaudited)

 

  

Three Months Ended

 
  

March 31,

 
  

2022

  

2021

 

Revenues

 $  $ 

Cost and expenses:

        

Depreciation

  6,730   6,242 

Research and development

  1,860,837   2,169,143 

General and administrative

  3,855,796   4,316,310 

Total costs and expenses

  5,723,363   6,491,695 

Operating loss

  (5,723,363)  (6,491,695)

Interest income

  879   1,982 

Net loss

  (5,722,484)  (6,489,713)

Net loss per share—basic and diluted

 $(0.12) $(0.14)

Weighted average number of common shares— basic and diluted

  47,879,597   45,546,106 

 

See accompanying notes to the unaudited condensed financial statements.

 

4

 

 

 

Genprex, Inc.

 

Condensed Statements of Changes in Stockholders' Equity (unaudited)

 

  

Common Stock

  

Additional

  

Accumulated

     
  

Shares

  

Amount

  

Paid-In Capital

  

Deficit

  

Total

 

Balance at December 31, 2020

  43,117,681  $43,118  $89,295,601  $(58,422,229) $30,916,490 

Issuance of stock for cash

  4,192,139   4,192   25,320,138      25,324,330 

Issuance of stock for services

  5,000   5   20,645      20,650 

Share based compensation

        651,088      651,088 

Net loss

           (6,489,713)  (6,489,713)

Balance at March 31, 2021

  47,314,820  $47,315  $115,287,472  $(64,911,942) $50,422,845 
                     

Balance at December 31, 2021

  47,874,708  $47,874  $119,246,970  $(78,017,853) $41,276,991 

Issuance of stock for cash

               

Issuance of stock for services

  5,000   5   17,495      17,500 

Share based compensation

        1,452,607      1,452,607 

Net loss

           (5,722,484)  (5,722,484)

Balance at March 31, 2022

  47,879,708  $47,879  $120,717,072  $(83,740,337) $37,024,614 

 

See accompanying notes to the unaudited condensed financial statements.

 

5

 

 

 

Genprex, Inc.

 

Condensed Statements of Cash Flows (unaudited)

 

  

Three Months Ended March 31,

 
  

2022

  

2021

 

Cash flows from operating activities:

        

Net loss

 $(5,722,484) $(6,489,713)

Adjustments to reconcile net loss to net cash used in operating activities:

        

Depreciation

 $6,730   6,242 

Share based compensation

 $1,470,107   671,738 

Changes in operating assets and liabilities:

        

Accounts receivable

 $(32,171)   

Prepaid expenses and other

 $(605,561)  187,282 

Accounts payable

 $279,783   146,493 

Other current liabilities

 $519,739   12,676 

Net cash used in operating activities

 $(4,083,857)  (5,465,282)

Cash flows from investing activities:

        

Additions to property and equipment

 $   (91,701)

Additions to intellectual property

 $(1,841)  (9,071)

Reductions (additions) to research and development supplies

 $12,160   (9,258)

Net cash provided (used) by investing activities

 $10,319   (110,030)

Cash flows from financing activities:

        

Proceeds from issuances of stock

 $   25,324,330 

Net cash provided by financing activities

 $   25,324,330 

Net decrease (increase) in cash and cash equivalents

 $(4,073,539)  19,749,018 

Cash and cash equivalents, beginning of period

 $38,628,876   27,319,685 

Cash and cash equivalents, end of period

 $34,555,337  $47,068,703 

 

See accompanying notes to the unaudited condensed financial statements.

 

6

 

 

GENPREX, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

 

 

Note 1 - Description of Business and Basis of Presentation

 

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.  Our oncology platform utilizes our non-viral ONCOPREX™ Nanoparticle Delivery System.  Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells.  Our diabetes technology is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

 

Oncology Platform

 

Our lead oncology drug candidate, REQORSA™ Immunogene Therapy, also sometimes referred to as GPX-001, initially is being developed in combination with top selling cancer drugs to treat Non-Small Cell Lung Cancer (“NSCLC”) and Small Cell Lung Cancer (“SCLC”). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA also has been shown to block mechanisms that create drug resistance and to be complementary with targeted drugs and immunotherapies.  We believe REQORSA’s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, who are not benefitting from current therapies.    

 

We currently are enrolling and treating patients in two Phase 1/2 clinical trials in NSCLC, our Acclaim-1 and Acclaim-2 clinical trials. The Acclaim-1 clinical trial (“Acclaim-1") is using a combination of REQORSA with AstraZeneca PLC’s Tagrisso® in patients with late-stage NSCLC with activating epidermal growth factor receptor ("EGFR") mutations, whose disease progressed after treatment with Tagrisso. The first patient was dosed in Acclaim-1 in February 2022. We expect the Phase 1 portion of Acclaim-1 to be completed by year end 2022. The Acclaim-2 clinical trial (“Acclaim-2”) is using a combination of REQORSA with Merck & Co.’s Keytruda® in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda. The first patient was dosed in Acclaim-2 in April 2022. We expect to complete the Phase 1 portion of Acclaim-2 by the end of the first quarter of 2023.

 

The Food and Drug Administration (“FDA”) has granted two Fast Track Designations, one for use of REQORSA in the patient population targeted in each of these trials. 

 

The TUSC2 gene is one of a series of genes whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").  We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of several cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates.

 

Diabetes Gene Therapy

 

In diabetes, we are developing a gene therapy that is exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) for the treatment of Type 1 and Type 2 diabetes. This potential treatment is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. The therapy utilizes a procedure in which an adeno-associated virus vector delivers Pdx1 and MafA genes to the pancreas. Our diabetes product candidate is currently being evaluated in preclinical studies at the University of Pittsburgh.

 

Capital Requirements, Liquidity and Going Concern Considerations

 

Our unaudited condensed financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying unaudited condensed financial statements, we have sustained substantial losses from operations since inception and have no current source of revenue. In addition, we have used, rather than provided, cash in our operations. We expect to continue to incur significant expenditures to further clinical trials for the commercial development of our product candidates.

 

Management recognizes that we must obtain additional capital resources to successfully commercialize our product candidates. To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, no assurances can be given that we will be successful in raising additional capital. If we are not able to timely and successfully raise additional capital, the timing of our clinical trials, financial condition and results of operations may be materially and adversely affected. These condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities.

 

7

 
 

Note 2 - Summary of Significant Accounting Policies

 

The Company’s unaudited condensed financial statements have been prepared in accordance with GAAP. However, they do not include all the information and footnotes required by GAAP for complete financial statements. In our opinion, the unaudited condensed financial statements include all adjustments (consisting of normal recurring accruals) necessary to make the unaudited condensed financial statements not misleading. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2022. For more complete financial information, these unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2021, included in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2022. A summary of our significant accounting policies consistently applied in the preparation of the accompanying unaudited condensed financial statements follows.

 

Capital Stock

 

The Company has the authority to issue up to 210,000,000 shares of stock consisting of 200,000,000 shares of common stock at a par value of $0.001 per share and 10,000,000 shares of preferred stock at a par value of $0.001 per share.

 

Use of Estimates

 

The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

We consider all highly liquid short-term investments with an initial maturity of three months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have cash equivalents in a money market account and had $34,178,486 and $38,392,886 in excess of FDIC insured limits of $250,000 at March 31, 2022 and December 31, 2021, respectively.

 

Fair Value of Financial Instruments

 

The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.

 

Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC 820’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC 820 classifies these inputs into the following hierarchy:

 

Level 1: Quoted prices for identical instruments in active markets.

 

Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

Level 3: Instruments with primarily unobservable value drivers.

 

8

 

Property and Equipment

 

Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.

 

Research and Development Costs

 

Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase 1/2 clinical trials and are expensed as incurred. Materials produced to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or clinical activities, or have spoiled.

 

Research and development supplies purchased and capitalized for future use were $3,010,243 and $3,022,403 at March 31, 2022 and December 31, 2021, respectively.

 

Intellectual Property

 

Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.

 

Accounting for Stock-Based Compensation

 

We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.

 

Long-Lived Assets

 

We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows. During the three months ended March 31, 2022, and the year ended December 31, 2021, there were no deemed impairments of our long-lived assets.

 

Recent Accounting Developments

 

Accounting pronouncements issued but not effective until after March 31, 2022, are not expected to have a significant effect on our financial condition, results of operations, or cash flows.

 

 

9

 

Note 3 - Intellectual Property

 

On February 11, 2020, we entered into an exclusive license agreement with the University of Pittsburgh for patented gene therapy technologies relating to the potential treatment of type 1 and type 2 diabetes. 

 

On May 4, 2020, we entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson relating to a portfolio of 16 patent applications and related technology for the treatment of cancer using the Company’s lead drug candidate, REQORSA, and immunotherapies. 

 

We own or have exclusive license agreements on 18 issued patents and 18 pending patent applications worldwide for technologies developed in-house or by researchers at the National Cancer Institute, MD Anderson, the University of Texas Southwestern Medical Center, and the University of Pittsburgh. These patents comprise various therapeutic, diagnostic, technical and processing claims. These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.

 

Note 4 - Equity

 

Registered Direct Offerings

 

On February 10, 2021, the Company completed a registered direct offering in which the Company sold to investors an aggregate of 4,000,000 shares of the Company's common stock at $6.25 per share. The Company received net proceeds of approximately $23.2 million after commissions and expenses.

 

Stock Issuances

 

During the three months ended March 31, 2022, we issued (i) 5,000 shares of common stock for services provided to us valued at $17,500 to the Chairman of our Scientific Advisory Board.

 

During the year ended December 31, 2021, we issued (i) 670,889 shares of common stock upon the exercise of options for cash proceeds of $677,912, and (ii) 86,138 shares of common stock for services provided to us valued at $156,045 to the Chairman of our Scientific Advisory Board and a consultant.

 

Preferred Stock

 

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, none of which are outstanding at March 31, 2022.

 

Common Stock

 

The Company is authorized to issue 200,000,000 shares of common stock with a par value of $0.001 per share, all of which are voting common stock. There were 47,879,708 shares of the Company's common stock outstanding at March 31, 2022.

 

10

 

Common Stock Purchase Warrants

 

Common stock purchase warrant activity for the period and year ended March 31, 2022, and December 31, 2021, respectively, is as follows:

 

  

Number of

  

Weighted Average

 
  

Warrants

  

Exercise Price

 

Outstanding at January 1, 2021

  2,154,747  $4.37 

Issued

  50,000   5.29 

Cancelled or expired

      

Exercised

      

Outstanding at December 31, 2021

  2,204,747  $4.39 

Issued

      

Cancelled or expired

      

Exercised

      

Outstanding at March 31, 2022

  2,204,747  $4.39 

Vested or expected to vest at March 31, 2022

      

Exercisable at March 31, 2022

  1,971,412  $4.62 

 

The Company did not issue warrants or record any share-based compensation associated with vesting of warrants during the three-month period ended March 31, 2022

 

In the year ended  December 31, 2021, the Company issued (i) a warrant to purchase up to 25,000 shares of common stock to a service provider at an exercise price of $7.22 per share, the fair market value of a share of common stock on the date of issuance and (ii) a warrant to purchase up to 25,000 shares of common stock to a service provider at an exercise price of $3.36 per share, the fair market value of a share of common stock on the date of issuance. During the year ended  December 31, 2021, we recorded share-based compensation of $200,282 associated with the vesting of warrants. 

 

On January 29, 2018, the Company entered into an agreement with a consultant whereby the Company agreed to grant warrants to purchase up to 6,000 shares of the Company's common stock at an exercise price of $5.00 per share in consideration of services valued at $30,000 provided to the Company. At March 31, 2022, the Company has not issued these warrants.

 

11

 
 

2018 Equity Incentive Plan

 

The Company’s board of directors and stockholders have approved and adopted the Company’s 2018 Equity Incentive Plan (“2018 Plan”), which became effective on the completion of the IPO on April 3, 2018. The 2018 Plan provides for the grant of incentive stock options that are intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended (“ISOs”), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and performance-based cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to the Company’s non-employee directors and consultants.

 

A total of 4,160,000 shares of common stock were initially available under the 2018 Plan, plus a number of shares of common stock (not to exceed 2,628,749 shares) subject to outstanding awards under our 2009 Equity Incentive Plan (the “2009 Plan”) as of the IPO that expire, are forfeited or otherwise terminate or that are used to cover the exercise price or applicable tax withholdings. No further grants will be made under the 2009 Plan.

 

In addition, the number of shares of common stock reserved for issuance under the 2018 Plan automatically increase on January 1 of each year, since  January 1, 2019, by 5% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our Board or a committee appointed to administer the 2018 Plan.

 

On  January 1, 2021, and 2022, the number of shares of common stock reserved for issuance under the 2018 Plan was increased by an aggregate of 2,155,884 and 2,393,735 shares, respectively. As of March 31, 2022, a total of 1,103,523 shares of common stock remains available for issuance under the 2018 Plan.

 

2018 Employee Stock Purchase Plan

 

The Company’s board of directors and stockholders approved and adopted the Company’s 2018 Employee Stock Purchase Plan (“ESPP”), which became effective on April 3, 2018. The ESPP has not yet been utilized as a benefit available to our employees. The ESPP authorizes the issuance of 208,500 shares of the Company’s common stock pursuant to purchase rights that may be granted to our eligible employees. The number of shares of common stock reserved for issuance under the ESPP is automatically increased on January 1 of each calendar year, beginning on January 1, 2019, by 2% of the total number of shares of the Company's common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the administrator of the ESPP. The administrator of the ESPP determined not to increase the number of shares reserved for issuance under the ESPP on  January 1, 2022.

 

Stock Options

 

As of March 31, 2022, the Company had outstanding stock options to purchase 10,961,363 shares of common stock that have been granted to various executives, employees, directors, and independent contractors. These options vest immediately or over periods ranging from 12 to 48 months, are exercisable for a period of up to ten years, and enable the holders to purchase shares of our common stock at exercise prices ranging from $0.015 to $9.80 per share. The per-share fair values of these options range from $0.015 to $7.93, based on Black-Scholes-Merton pricing models with the following assumptions:

 

Expected term (in years):

  10 

Risk-free rate:

  

0.07% – 2.63%

 

Volatility:

  

75.98% – 88.38%

 

Dividend yield:

  

0%

 

 

12

 

During the three-month period ended  March 31, 2022, the Company (i) granted stock options to purchase an aggregate of 2,404,562 shares of the Company's common stock with exercise prices ranging from $2.00 to $3.50 per share to executives and employees, and (ii) cancelled options to purchase 17,500 shares of common stock at an exercise price of $2.00 per share in connection with the termination of employment of an employee. 

 

In the year ended  December 31, 2021, the Company (i) granted stock options to purchase an aggregate of 2,519,628 shares of the Company's common stock with exercise prices ranging from $2.72 to $7.22 per share to executives, employees, board members, and consultants, (ii) cancelled options to purchase 118,507 shares of common stock with exercise prices ranging from $1.45 to $7.22 per share in connection with the termination of employment of employees, and (iii) issued 670,889 shares of the Company's common stock upon the exercise of options held by consultants, a former board member, and a former executive, with exercise prices ranging from $0.015 to $2.15 per share.

 

The weighted average remaining contractual term for the outstanding options at  March 31, 2022 and  December 31, 2021 is 7.61 and 7.24 years, respectively.
 

Stock option activity for the three months ended March 31, 2022, and year ended  December 31, 2021 is as follows:

 

  

Number of

  

Weighted Average

 
  

Shares

  

Exercise Price

 

Outstanding at January 1, 2021

  6,844,069  $2.81 

Options granted

  2,519,628   4.26 

Options exercised

  (670,889)  1.01 

Options expired

  (118,507)  3.00 

Outstanding at December 31, 2021

  8,574,301  $3.35 

Options granted

  2,404,562   2.30 

Options exercised

      

Options expired or cancelled

  (17,500)  2.00 

Outstanding at March 31, 2022

  10,961,363  $3.13 

Vested or expected to vest at March 31, 2022

  605,648   4.45 

Exercisable at March 31, 2022

  5,981,155  $3.20 

 

Share-Based Compensation

 

For the three months ended March 31, 2022, the Company's total share-based compensation was approximately $1.5 million, nearly all of which represents the vesting of options issued to executives, employees, and service providers. As of  March 31, 2022, the Company’s total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, employees, board members, and service providers and not yet recognized was approximately $10.6 million. The Company expects to record this stock-based compensation expense over the next three years using a graded vesting method. As of March 31, 2022, the weighted average term over which these expenses are expected to be recognized is 2.06 years. 

 

As of March 31, 2022, there are no performance-based stock option awards outstanding and one performance-based warrant outstanding issued to a service provider. The Company’s total compensation cost related to the non-vested performance-based warrant not yet recognized was approximately $300,000. The entirety of this warrant may be recognized and recorded upon the achievement of certain milestones.

 

13

 
 
 

Note 5 - Related Party Transactions

 

Introgen Research Institute

 

Introgen Research Institute (“IRI”) is a Texas-based technology company formed by Rodney Varner, our President, Chief Executive Officer and Chairman of the Board of which Mr. Varner is the sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In April 2009, prior to Mr. Varner becoming an officer and director of our Company in August 2012, we entered into an Assignment and Collaboration Agreement with IRI, providing us with the exclusive right to commercialize a portfolio of intellectual property. This agreement was amended in 2011 to include additional sublicensing of additional intellectual property made available to IRI from MD Anderson.

 

 

Note 6 - Commitments and Contingencies

 

Leases

 

On April 16, 2018, the Company executed a space utilization agreement with the Board of Regents of the University of Texas System to establish and lease offices at the Dell Medical School in Austin, Texas. On March 23, 2021, the Company was informed by Dell Medical School that the University of Texas desired to use the space and not renew the space utilization agreement. The lease terminated on April 30, 2021, and our employees all currently work virtually while we evaluate future space needs post the COVID-19 pandemic. 

 

14

 

Commitments

 

MD Anderson Cancer Center

 

The Company entered into a clinical study agreement with the MD Anderson, to administer the Company’s Phase 1/2 clinical trial, combining REQORSA and Tarceva in Stage 4 lung cancer patients. The trial was expected to run through the end of 2018 with a projected total cost of approximately $2 million. Payments are due and payable when invoiced throughout the clinical trial period. The agreement may be terminated at any time. In 2020, the Company received Fast Track Designation ("FTD") from the FDA for its Acclaim-1 trial which combines REQORSA plus Tagrisso in patients with stage III or IV NSCLC with EGFR mutations that progressed after treatment with Tagrisso. Given the FTD and with Tagrisso now considered a new standard of care in the U.S. for NSCLC with an EGFR mutation, the Company is no longer enrolling patients in its ONC-002 study and, in June 2021, initiated its Acclaim-1 trial.

 

In July 2018, the Company entered into a two-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on the combination of REQORSA with an immunotherapy with a projected total cost of approximately $2 million. Payments are due and payable when invoiced throughout the period. The agreement may be terminated at any time. This agreement has been extended through May 2022.

 

In 2011, the Company agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated with certain technologies and intellectual property originally licensed to another party under a 1994 License Agreement with MD Anderson (“Original MD Anderson License Agreement”). These technologies and intellectual property were later sublicensed to IRI (the “IRI Sublicense”). The Company also agreed to pay royalties of 1% on sales of certain licensed products for a period of 21 years following the termination of the later of the Original MD Anderson License Agreement and the IRI Sublicense. The Company assumed patent prosecution costs and an annual minimum royalty of $20,000 payable to the National Institutes of Health.

 

On March 3, 2021, the Company entered into an amendment (the “MD License Amendment”) to the Patent and Technology License Agreement dated May 4, 2020, with MD Anderson. The MD License Amendment grants the Company a worldwide, exclusive, sublicensable license to an additional portfolio of six patents and one patent application and related technology for methods for treating cancer by administration of a TUSC2 therapy in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy. Pursuant to the MD License Amendment, the Company agreed to (i) pay annual maintenance fees ranging from the mid five figures to the low six figures, (ii) total milestone payments of $6,150,000, (iii) a one-time fee in the mid five figures and (iv) certain patent related expenses.

 

 

15

 

National Institutes of Health

 

Our $191,393 payment obligation to the National Institutes of Health (“NIH”) represented a current obligation, of which $15,393 of 2016 patent prosecution costs were paid in the fourth quarter of 2016 and $176,000 was included in accounts payable at December 31, 2016 (consisting of accrued annual royalties of $140,000 and patent costs of $36,000). During the first quarter of 2017, we modified the terms of our accrued royalty obligation to NIH. Under the modified agreement, NIH agreed to extinguish $120,000 of the accrued royalties payable to it in consideration of payment by us of (i) accrued patent costs of $36,000, (ii) a royalty payment of $20,000, and (iii) a contingent payment of $240,000, increasing by $20,000 per year starting in 2018, to be paid upon our receipt of FDA approval. The payments for the patent costs of $36,000 and royalties of $20,000 were paid during the second quarter of 2017.

 

As a result of our modified agreement with the NIH, we have recognized the exchange of the $120,000 fixed obligation for the $240,000 contingent obligation as a $120,000 reduction to intellectual property expense (classified within general and administrative expense) during the first quarter of 2017. The $240,000 contingent obligation, which increases annually by $20,000 and was $340,000 as of March 31, 2022, will be recognized when we obtain regulatory approval (the event that triggers the payment obligation).

 

University of Pittsburgh

 

Pursuant to the Exclusive License Agreement dated February 11, 2020 by and between the Company and the University of Pittsburgh, the Company agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the first three years and $40,000 for each subsequent year following the first anniversary of the agreement, (iii) royalties ranging from 1.5% to 3% of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the first commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) 20 years after the first commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.

 

Contingencies

 

From time to time, we may become subject to threatened and/or asserted claims arising in the ordinary course of our business. Management is not aware of any matters, either individually or in the aggregate, that are reasonably likely to have a material impact on our financial condition, results of operations or liquidity.

 

16

 
 

Note 7 - Significant Events

 

The COVID-19 pandemic continues to have a major impact in the U.S. and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines may result in continued impact from this pandemic in the future, which could adversely impact our operations. Through March 31, 2021, the Company had not experienced any material impact on its financial results or operations as a result of the COVID-19 pandemic. Beginning in June 2021, the Company experienced delays in engaging clinical sites as a result of a backlog of clinical trial protocols requiring review created by an accumulation of clinical trial protocols. The Company continues to closely monitor the impact of the COVID-19 pandemic on its business and workforce.

 

 

Note 8 - Subsequent Events

 

Share Issuance

On April 1, 2022, the Company issued 5,000 shares of its common stock to the Chairman of our Scientific Advisory Board in consideration for services.

 

Option Issuance

On April 18, 2022, the Company issued a stock option grant under the 2018 Equity Incentive Plan to purchase a total of 17,500 shares of common stock to a new employee at the fair market value of the common stock on the date of issuance. 

 

Warrant Exercise

On May 4, 2022, we issued 13,643 shares of common stock to a placement agent associated with our November 2019 registered direct offering pursuant to the cashless exercise of a warrant. The remaining balance of the warrant representing the right to purchase 10,291 shares of common stock was cancelled.

 

 

17

 
 
 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

You should read the following discussion and analysis of our financial condition and results of operations together with our interim condensed financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled Risk Factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as may be amended, supplemented or superseded from time to time by other reports we file with the SEC. All amounts in this report are in U.S. dollars, unless otherwise noted.

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

 

This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Quarterly Report contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this Quarterly Report about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and “would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. 

 

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this Quarterly Report. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to:

 

 

Market conditions;

  

 

Our capital position;

  

 

Our ability to compete effectively and with larger better financed pharmaceutical companies;

  

 

Our uncertainty of developing marketable products;

  

 

Our ability to develop and commercialize our products;

  

 

Our ability to obtain regulatory approvals;

  

 

Our ability and third parties’ ability to maintain and protect intellectual property rights;

  

 

Our ability to raise additional future financing and possible lack of financial and other resources;

  

 

The ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole;

  

 

The success of our clinical trials through all phases of clinical development;

  

 

Any delays in regulatory review and approval of our current and future product candidates;

  

 

Our dependence on third-party manufacturers to supply or manufacture our products;

  

 

Our ability to control product development costs;

  

 

Our ability to attract and retain key employees;

 

18

 

 

Our ability to enter into new strategic collaborations, licensing or other arrangements;

 

 

Changes in government regulation affecting product candidates that could increase our development costs;

 

 

Our involvement in patent and other intellectual property litigation that could be expensive and divert management’s attention;

 

 

The possibility that there may be no market acceptance for our products; and

 

 

Changes in third-party reimbursement policies which could adversely affect potential future sales of any of our products that are approved for marketing.

 

The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements, which speak only as of the date of this Quarterly Report or the date of the document incorporated by reference into this Quarterly Report.  Except as required by law, we assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this Quarterly Report or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements contained in this Quarterly Report. All forward-looking statements are expressly qualified in their entirety by the cautionary statements contained in this section.

 

Overview

 

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.  Our oncology platform utilizes our non-viral ONCOPREX™ Nanoparticle Delivery System.  Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells.  Our diabetes technology is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

 

Oncology Platform

 

Our lead oncology drug candidate, REQORSA™ Immunogene Therapy, also sometimes referred to as GPX-001, initially is being developed in combination with top selling cancer drugs to treat Non-Small Cell Lung Cancer (“NSCLC”) and Small Cell Lung Cancer (“SCLC”). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA also has been shown to block mechanisms that create drug resistance and to be complementary with targeted drugs and immunotherapies.  We believe REQORSA’s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, who are not benefitting from current therapies.

 

We currently are enrolling and treating patients in two Phase 1/2 clinical trials in NSCLC, our Acclaim-1 and Acclaim-2 clinical trials. The Acclaim-1 clinical trial (“Acclaim-1") is using a combination of REQORSA with AstraZeneca PLC’s Tagrisso® in patients with late-stage NSCLC with activating epidermal growth factor receptor ("EGFR") mutations, whose disease progressed after treatment with Tagrisso. The first patient was dosed in Acclaim-1 in February 2022. We expect the Phase 1 portion of Acclaim-1 to be completed by year end 2022. The Acclaim-2 clinical trial (“Acclaim-2”) is using a combination of REQORSA with Merck & Co.’s Keytruda® in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda. The first patient was dosed in Acclaim-2 in April 2022. We expect to complete the Phase 1 portion of Acclaim-2 by the end of the first quarter of 2023.

 

The Food and Drug Administration (“FDA”) has granted two Fast Track Designations, one for use of REQORSA in the patient population targeted in each of these trials. 

 

The TUSC2 gene is one of a series of genes whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").  We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of several cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates.

 

Diabetes Gene Therapy

 

In diabetes, we are developing a gene therapy that is exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) for the treatment of Type 1 and Type 2 diabetes. This potential treatment is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. The therapy utilizes a procedure in which an adeno-associated virus vector delivers Pdx1 and MafA genes to the pancreas. Our diabetes product candidate is currently being evaluated in preclinical studies at the University of Pittsburgh.

 

19

 

JOBS Act

 

On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Although we are an emerging growth company, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. We have implemented all new accounting pronouncements that are in effect and may affect our financial statements, and we do not believe that there are any other new accounting pronouncements that have been issued that would have a material impact on our financial position or results of operations.

 

Notwithstanding the foregoing, subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain exemptions, including, without limitation, the exemption from the requirements (i) to provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act, and (ii) to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of our initial public offering; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

 

Recently Issued Accounting Pronouncements

 

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our financial statements appearing in this Quarterly Report on Form 10-Q.

 

Critical Accounting Policies and Significant Judgments and Estimates

 

Our condensed financial statements have been prepared in accordance with generally accepted accounting principles in the U.S. ("GAAP"). The preparation of these condensed financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

We believe that the following accounting policies are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain.

 

Research and Development Costs

 

We record accrued expenses for costs invoiced from research and development activities conducted on our behalf by third-party service providers, which include the conduct of preclinical studies and clinical trials and contract research, manufacturing, and testing activities. We record the costs of research and development activities based upon the amount of services provided, and we include these costs in accrued liabilities in the condensed balance sheets and within research and development expense in the condensed statements of operations. These costs are a significant component of our research and development expenses. Purchased materials to be used in future research are capitalized and included in research and development supplies.

 

We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment in any of our clinical trials may vary from our estimates and could result in our reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from contract research organizations ("CROs") and other third-party service providers. To date, there have been no material differences from our accrued expenses to actual expenses. 

 

20

 

Income Taxes

 

Deferred tax assets or liabilities are recorded for temporary differences between financial statement and tax basis of assets and liabilities, using applicable rates in effect for the year in which the differences are expected to reverse. A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. We have provided a full valuation allowance on our deferred tax assets, which primarily consist of cumulative net operating losses from April 1, 2009 (inception) to March 31, 2022. Due to our history of operating losses since inception and losses expected to be incurred in the foreseeable future, a full valuation allowance was considered necessary.

 

Impairment of Long-Lived Assets

 

Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset’s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.

 

Components of our Results of Operations and Financial Condition

 

Operating expenses

 

We classify our operating expenses into three categories: research and development, general and administrative and depreciation.

 

Research and development. Research and development expenses consist primarily of:

 

 

costs incurred to conduct research, such as the discovery and development of our current and potential product candidates;

  costs related to the production and storage of supplies for engineering purposes and storage and usage of clinical supplies, including waste created in the process of producing clinical materials, spoilage, and testing of clinical materials;
  costs related to the use of contract manufacturers, manufacturing consultants, testing organizations, cold-storage facilities, and logistics service providers;
 

fees paid to clinical consultants, clinical trial sites and vendors, including CROs in conjunction with implementing and monitoring our clinical trials and acquiring and evaluating clinical trial data, including all related fees, such as patient screening fees, laboratory work, and statistical compilation and analysis; 

 

costs related to compliance with drug development regulatory requirements; and

  costs related to staffing and personnel associated with research and development activities, including wages, taxes, benefits, leases, overheads, supplies, and share-based compensation.

 

We recognize all research and development costs as they are incurred. Clinical trial costs, contract manufacturing and other development costs incurred by third parties are expensed as the contracted work is performed.

 

We expect our research and development expenses to increase in the future as we advance our current and future product candidates into and through clinical trials, as we pursue regulatory approval of our current and potential product candidates in the United States and Europe, and as we expand our research programs to include new therapies and new therapy combinations. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our current and potential product candidates may be affected by a variety of factors including the quality of our current and potential product candidates, early clinical data, investment in our clinical program, competition, manufacturing capability and commercial viability, and limited contracted partners. We may never succeed in achieving regulatory approval for any of our current or future product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if at all.

 

General and administrative. General and administrative expense consists of personnel related costs, which include salaries, as well as the costs of professional services, such as accounting and legal, travel, facilities, information technology and other administrative expenses. We expect our general and administrative expense to increase in future periods due to the anticipated growth of our business and related infrastructure as well as accounting, insurance, investor relations, and other costs associated with being a public company.

 

Depreciation. Depreciation expense consists of depreciation from our fixed assets consisting of our property, equipment, and furniture. We depreciate our assets over their estimated useful life. We estimate furniture and computer and office equipment to have a five-year life.

 

21

 

Results of Operations

 

Comparison of the Three Months Ended March 31, 2022, and 2021

 

The following summarizes our results of operations for the three months ended March 31, 2022, and 2021.

 

Research and Development Expense

 

R&D expense for the three months ended March 31, 2022, was $1,860,837, compared to $2,169,143 for the three months ended March 31, 2021. Despite the growth in our R&D headcount since the first quarter of 2021 and its attendant increase in R&D expense, our R&D expense in the first quarter of 2022 compared to the first quarter of 2021 decreased $308,306, or 14%, primarily due to advancements and expenditures made in our manufacturing program in the first quarter of 2021 to support our Acclaim-1 and Acclaim-2 clinical trials which started enrollment and patient treatment in the first half of 2022. 

 

General and Administrative Expense

 

General and administrative ("G&A") expense for the three months ended March 31, 2022, was $3,855,796, compared to $4,316,310 for the three months ended March 31, 2021, or a decrease of $460,514, or 11%. The larger G&A expense in the three months ended March 31, 2021, was primarily due to a one-time finance fee of $1,750,000 in connection with a registered direct offering during the period. The decrease in G&A expenses in the first quarter of 2022 is offset by increases in equity-based compensation due to the vesting of stock options by employees and consultants and growth of our G&A headcount, associated personnel expenses, and insurance premiums during the three months ended March 31, 2022.

 

Interest Income. Interest income was $879 and $1,982 for the three months ended March 31, 2022, and 2021, respectively, representing a decrease of $1,103, or 56%. The decreases associated with interest income for the three months ended March 31, 2022 were due to changes in the cash balances associated with money market instruments.

 

Depreciation Expense. Depreciation expense was $6,730 and $6,242 for the three months ended March 31, 2022, and 2021, respectively, representing an increase of $488, or 8%. The changes in associated depreciation expense for the three months ended March 31, 2022 were due to the timing of purchases of computer equipment for new employees.

 

Net Loss.  We had a net loss of $5,722,484 and $6,489,713 for the three months ended March 31, 2022, and 2021, respectively, representing a decrease of $767,229, or 12%. The larger net loss during the three months ended March 31, 2021 is principally due to a one-time finance fee of $1,750,000 in connection with a registered direct offering during the period. The one-time finance fee was offset during the three months ended March 31, 2022​​, as our headcount grew from 13 to 19 employees since March 31, 2021. 

 

Liquidity and Capital Resources

 

From inception through March 31, 2022, we have never generated revenue from product sales and have incurred net losses in each year. As of March 31, 2022, we had an accumulated deficit of $83,740,337. We have funded our operations primarily through the sale and issuance of capital stock. For the year ended December 31, 2021, we sold an aggregate of 4,000,000 shares of common stock for total net proceeds of $23,192,500 pursuant to a registered direct offering and issued 670,889 shares of common stock upon the exercise of options for gross proceeds of $677,912. We did not sell any shares of common stock during the three months ended March 31, 2022. 

 

22

 

 

As of March 31, 2022, we had $34,555,337 in cash and cash equivalents.   

 

We do not expect to generate revenue from product sales unless and until we successfully complete development of, obtain regulatory approval for and begin to commercialize one or more of our current or potential product candidates, which we expect will take several years and which is subject to significant uncertainty. Accordingly, we anticipate that we will need to raise additional capital to fund our future operations, which include conducting our Acclaim-1 and our Acclaim-2 clinical trials. Both trials are currently open for enrollment. The first patient in Acclaim-1 was dosed in February 2022 and the first patient in Acclaim-2 was dosed in April 2022. We expect the Phase 1 portion of the Acclaim-1 trial to be completed by year end 2022 and we expect the Phase 1 portion of the Acclaim-2 trial to be completed by the end of the first quarter of 2023. Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings and debt financings and we may seek to raise additional capital through strategic collaborations. However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or commercialization efforts or grant rights to others to develop or market product candidates that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to curtail or cease our operations. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market conditions or strategic considerations.

 

Based on our current cash and cash equivalents, we estimate that we will be able to fund our expenditure requirements for our current operations and planned clinical trial activities into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently plan due to economic factors, such as inflation, incorrect assumptions, or due to a decision to expand our activities, or innovate existing activities beyond those currently planned. We also have been experiencing delays in engaging clinical sites for our Acclaim-1 and Acclaim-2 trials because of a backlog of clinical trial protocols at the sites requiring review created by an accumulation of protocols while clinical trials have been widely disrupted during the COVID-19 pandemic and workforce shortages impacting the U.S. economy in general. Although, continued delays will enable us to fund our expenditure requirements for our current operations and planned clinical trial activities longer, we would not be advancing our clinical trials as anticipated and utilizing our available capital resources to support our operations only.

 

The following table sets forth the primary sources and uses of cash and cash equivalents during the three months ended March 31, 2022, and 2021:

 

   

Three Months Ended March 31,

 
   

2022

   

2021

 

Net cash used in operating activities

  $ (4,083,857 )   $ (5,465,282 )

Net cash provided (used) by investing activities

    10,319       (110,030 )

Net cash provided by financing activities

          25,324,330  

Net decrease (increase) in cash and cash equivalents

  $ (4,073,539 )   $ 19,749,018  

 

Cash used in operating activities

 

Net cash used in operating activities was $4,083,857 and $5,465,282 for the three months ended March 31, 2022, and 2021, respectively, or a decrease of $1,381,425, or 25%. The one-time finance fee of $1,750,000 in the three months ended March 31, 2021, was offset in the three months ended March 31, 2022 due to our headcount growing from 13 to 19 employees as well as the associated personnel and insurance expenses. 

 

Cash provided (used) in investing activities

 

Net cash provided by investing activities was $10,319 for the three months ended March 31, 2022, and the net cash used by investing activities was $110,030 for the three months ended March 31, 2021. This decrease of $120,349, or 109%, was due to timing and use of materials for our clinical trials. 

 

Cash provided by financing activities

 

Net cash provided by financing activities was $0 and $25,324,330 during the three months ended March 31, 2022, and 2021, respectively. The decrease of $25,324,330, or 100%, in net cash provided by financing activities was due to significant sales of common stock in capital raising activities and option and warrant exercises during the three months ended March 31, 2021, compared to the three months ended March 31, 2022, in which we did not sell any common stock. 

 

23

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of March 31, 2022, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were not effective due to the material weakness in our internal control over financial reporting due to the lack of segregation of duties. 

 

Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to maintain effective segregation of duties on our assessment of our internal control over financial reporting and has concluded that the control deficiency represents a material weakness. 

 

In response to the material weakness described above, during the quarter ended March 31, 2022, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with GAAP. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

 

Remediation Plans

 

Management is actively engaged in remediation efforts to address the material weakness identified in the management’s evaluation of internal controls and procedures. The remediation efforts, which have been or are in the process of being implemented, are intended to address the identified material weakness, and include

 

 

new accounting software, processes, and workflows to further segregate duties among limited accounting staff;

 

 

specific review procedures, including the added involvement of our General Counsel to review all accounting transactions following a given period in an effort to enhance accuracy of reporting;

 

 

specific review procedures, including the added involvement of our manufacturing staff to enhance controls associated with the tracking and reporting of inventory values in our supply chain; 

 

 

the formation of a formal Disclosure Committee that has oversight responsibility for the accuracy and timeliness of disclosures made by us through the establishment of controls and procedures and the monitoring of their integrity and effectiveness; and

 

 

additional hiring of staff and development of accounting processes and policies to further segregate accounting responsibilities. 

 

During the quarter ended March 31, 2022, we took actions to remediate the material weakness relating to our internal controls over financial reporting including the evaluation and improvement of procedures and processes associated with new accounting software and workflows to segregate duties among our accounting staff.

 

As Management continues to evaluate and work to improve its internal control over financial reporting, we may take additional measures to address control deficiencies, or we may modify certain of the remediation measures described above. While remediation efforts are active, management requires additional time to demonstrate the operating effectiveness of our remediation efforts. The material weaknesses cannot be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

 

Changes in Internal Control over Financial Reporting

 

Except as described above, there were no changes in our internal control over financial reporting during the quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting

 

Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to risks, including that the controls may become inadequate because of changes in conditions or that the degree of compliance with our policies or procedures may deteriorate.

 

24

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition, or operating results.

 

Item 1A. Risk Factors

 

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

On January 3, 2022, we issued 5,000 shares of our common stock to a consultant in consideration for services. The foregoing issuance of securities was not registered under the Securities Act or the securities laws of any state, and the securities were offered and issued in reliance on the exemption from registration under the Securities Act afforded by Section 4(a)(2).

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

25

 

 

INDEX TO EXHIBITS

 

Exhibit

Number

 

Description of Exhibit

     

31.1*

 

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

31.2*

 

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

32.1*

 

Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

101.INS*

 

Inline XBRL Instance Document.

 

 

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

 

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

     
104*   Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.

 

26

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

GENPREX, INC.

 

 

 

Date: May 13, 2022

By:

/s/ J. Rodney Varner

 

 

J. Rodney Varner

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

 

By:

/s/ Ryan M. Confer

 

 

Ryan M. Confer

 

 

Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

27
EX-31.1 2 ex_342874.htm EXHIBIT 31.1 ex_342874.htm

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF GENPREX, INC. PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, J. Rodney Varner, certify that:

 

 

1.

I have reviewed this quarterly report on Form 10-Q of Genprex, Inc., a Delaware corporation (the “registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

 

 

 

 

 

 

 

 

 

 

 

 Date: May 13, 2022

By:

/s/ J. Rodney Varner

 

 

 

J. Rodney Varner 

 

 

 

Chief Executive Officer 

 

    (Principal Executive Officer)  

 

 
EX-31.2 3 ex_342875.htm EXHIBIT 31.2 ex_342875.htm

Exhibit 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER OF GENPREX, INC. PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ryan M. Confer, certify that:

 

 

1.

I have reviewed this quarterly report on Form 10-Q of Genprex, Inc., a Delaware corporation (the “registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: May 13, 2022

By:

/s/ Ryan M. Confer

 

 

Ryan M. Confer

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 
EX-32.1 4 ex_342876.htm EXHIBIT 32.1 ex_342876.htm

Exhibit 32.1

 

CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Genprex, Inc. (the “Company”) for the quarter ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, J. Rodney Varner, Chief Executive Officer of the Company, and Ryan M. Confer, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

 

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 Date: May 13, 2022

By:

/s/ J. Rodney Varner

 

 

 

J. Rodney Varner 

 

 

 

Chief Executive Officer 

 

    (Principal Executive Officer)  
       
       
  By: /s/ Ryan M. Confer  
    Ryan M. Confer  
    Chief Financial Officer  
    (Principal Financial and Accounting Officer)  

 

This certification accompanies the Report, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

 

 

 
EX-101.SCH 5 gnpx-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Description of Business and Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Intellectual Property link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Equity link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Significant Events link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 4 - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 4 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 4 - Equity - Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 4 - Equity - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 8 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 gnpx-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 gnpx-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 gnpx-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield: Fair Value of Financial Instruments, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies Note 4 - Equity Risk-free rate: Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) Note 4 - Equity - Assumptions (Details) Note 4 - Equity - Stock Option Activity (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Volatility: Share based compensation us-gaap_ShareBasedCompensation us-gaap_OtherAssetsNoncurrent Total other assets us-gaap_LiabilitiesCurrent Total current liabilities Expected term (in years): (Year) Other current liabilities Revenues Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease Finite-Lived Intangible Assets, Period Increase (Decrease), Total Share-Based Payment Arrangement, Option, Activity [Table Text Block] Research and Development Expense, Policy [Policy Text Block] Depreciation Intangible Assets Disclosure [Text Block] us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Vested or expected to vest, number of shares (in shares) Vested or expected to vest, weighted average exercise price (in dollars per share) Exercisable, weighted average exercise price (in dollars per share) us-gaap_AssetsCurrent Total current assets Share-Based Payment Arrangement [Policy Text Block] Stockholders' Equity Note Disclosure [Text Block] Exercisable, number of shares (in shares) gnpx_ResearchAndDevelopmentAssetsCurrent Research and Development Assets, Current The amount of research and development assets classified as current. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) Common stock $0.001 par value: 200,000,000 shares authorized; 47,879,708 and 47,874,708 shares issued and outstanding at March 31, 2022, and December 31, 2021, respectively Adjustments to reconcile net loss to net cash used in operating activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Common stock, shares authorized (in shares) Common Stock, Shares Authorized (in shares) us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities Payment for Contingent Consideration Liability, Operating Activities Accounts payables Common stock, shares issued (in shares) Options expired, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) Stockholders' Equity, Policy [Policy Text Block] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Options granted, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Options exercised, weighted average exercise price (in dollars per share) us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) Statistical Measurement [Domain] Maximum [Member] Minimum [Member] us-gaap_PaymentsForRoyalties Payments for Royalties us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Outstanding, number of shares (in shares) Outstanding, number of shares (in shares) Statistical Measurement [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares) Options expired (in shares) Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding Preferred stock, shares issued (in shares) Intangible Assets, Finite-Lived, Policy [Policy Text Block] us-gaap_PolicyTextBlockAbstract Accounting Policies Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) gnpx_CapitalStockSharesAuthorized Capital Stock, Shares Authorized (in shares) Capital stock shares authorized. Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) us-gaap_PaymentsToAcquireIntangibleAssets Payments to Acquire Intangible Assets Additions to intellectual property us-gaap_AccruedRoyaltiesCurrent Accrued Royalties, Current us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property and equipment us-gaap_AccountsPayableOtherCurrent Accounts Payable, Other, Current us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) Issued, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights issued during period. Current liabilities: Issued, number of warrants (in shares) Class of Warrant or Right, Issued in Period (in shares) The number of warrants or rights issued during period. gnpx_ClassOfWarrantOrRightExercisedDuringPeriod Exercised, number of warrants (in shares) The number of warrants or rights exercised during period. gnpx_ClassOfWarrantOrRightCancelledDuringPeriod Class of Warrant or Right, Cancelled During Period (in shares) Cancelled or expired, number of warrants (in shares) The number of warrants or rights cancelled during period. us-gaap_Assets Total assets us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Cash flows from operating activities: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Statement [Line Items] Accounts receivable Additional paid-in capital Stockholders’ equity: Property, Plant and Equipment, Policy [Policy Text Block] Award Type [Domain] Current assets: Award Type [Axis] Net loss Net loss us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Intellectual property, net Interest income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease (increase) in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Other assets: Sale of Stock [Axis] Sale of Stock [Domain] Performance Shares [Member] us-gaap_OperatingIncomeLoss Operating loss Share-Based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Warrant [Member] us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided (used) by investing activities Prepaid expenses and other gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares) Value of stock issued in shares for exercise of cashless warrants. MD Anderson [Member] Represents MD Anderson. Counterparty Name [Axis] Research Agreement [Member] Represents the research agreement. Counterparty Name [Domain] Clinical Trial Agreement [Member] Represent the clinical trial agreement. Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] gnpx_LongTermContractEstimatedCost Long Term Contract, Estimated Cost Estimated total cost of of long term contract. Commitments and Contingencies Disclosure [Text Block] gnpx_RoyaltyOnSalesPercentage Royalty on Sales, Percentage Percentage of sales of royalty. Property and equipment, net National Institute of Health [Member] Represents the national institute of health (NIH). gnpx_AccruedPatentCostsCurrent Accrued Patent Costs, Current Accrued patent costs current. gnpx_ContingentPaymentsAnnualIncrease Contingent Payments Annual Increase Annual increase in contingent payment. gnpx_RoyaltyPaymentAnnualMinimum Royalty Payment, Annual Minimum Minimum of annual royalty payment. gnpx_RoyaltyTerms Royalty Term (Year) Terms of the royalty agreement, as a percentage of net sales of licensed technologies . us-gaap_AccountsPayableCurrentAndNoncurrent Accounts Payable, Total The 2009 Plan [Member] Represents the 2009 plan. The 2018 Equity Incentive Plan [Member] Represents information related to the 2018 equity incentive plan. The 2018 Employee Stock Purchase Plan [Member] Represents information related to the 2018 employee stock purchase plan. gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year Share based compensation arrangement by share based payment award percentage applied on outstanding shares of common stock for automatically increase on each year. Bear Creek Capital Warrants [Member] Related to Bear Creek Capital warrants. FundAthena, Inc [Member] Represent FundAthena, Inc. Warrants Issued for Services [Member] Represents warrant issued fro services. gnpx_ClassOfWarrantOrRightVestedOrExpectedToVest Vested or expected to vest, number of warrants (in shares) The number of warrants or rights vested or expected to vest. us-gaap_CostsAndExpenses Total costs and expenses gnpx_ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice Vested or expected to vest, weighted average exercise price (in dollars per share) The weighted average exercise price of warrants or rights vested or expected to vest. Cash flows from investing activities: Cost and expenses: Scenario [Domain] Retained Earnings [Member] us-gaap_ExtinguishmentOfDebtAmount Extinguishment of Debt, Amount Proceeds from issuances of stock Proceeds from Issuance of Common Stock Scenario [Axis] Accounts payable Additional Paid-in Capital [Member] Common Stock [Member] Related Party Transactions Disclosure [Text Block] Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) Outstanding, number of warrants (in shares) Outstanding, number of warrants (in shares) us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_OtherExpenses Other Expenses, Total General and administrative Cash and cash equivalents us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities Bear Creek Capital Warrant One [Member] Related to Bear Creek Capital warrant one. Bear Creek Capital Warrant Two [Member] Related to Bear Creek Capital warrant two. us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense us-gaap_LegalFees Legal Fees Cash and Cash Equivalents, Policy [Policy Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding, Ending Balance (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding, Ending Balance (in shares) Title of 12(b) Security Current Fiscal Year End Date us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other Document Fiscal Period Focus Document Fiscal Year Focus gnpx_LicenseAgreementMilestonePayment License Agreement Milestone Payment Disclosure of milestone payments made for License Agreements. Document Period End Date Entity File Number Entity Ex Transition Period Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount Warrant, Nonvested Award, Cost Not yet Recognized, Amount Amount of cost not yet recognized for nonvested warrant. Performance-based Warrant [Member] Related to performance-based warrant. us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment, Long-Lived Asset, Held-for-Use, Total us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Share based compensation Entity Tax Identification Number Entity Central Index Key Entity Registrant Name gnpx_ClassOfWarrantOrRightExercisableExercisePrice Exercisable, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights exercisable. Exercisable, number of warrants (in shares) The number of warrants or rights exercisable. Entity [Domain] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Weighted average number of common shares— basic and diluted (in shares) Entity Address, City or Town Entity Address, Postal Zip Code Net loss per share—basic and diluted (in dollars per share) Entity Address, State or Province Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Trading Symbol gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies Reductions (additions) to research and development supplies The cash outflow or inflow for research and development supplies. Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) Options exercised, number of shares (in shares) us-gaap_TableTextBlock Notes Tables us-gaap_OtherCommitment Other Commitment, Total us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised Options granted, number of shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Cash flows from financing activities: Registered Direct Offering [Member] Represents Registered Direct Offering. Investors [Member] Represents the investors of the company. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Issuance of stock for cash (in shares) Stock Issued During Period, Shares, New Issues (in shares) Issuance of stock for services Stock Issued During Period, Value, Issued for Services Issuance of stock for services (in shares) Stock Issued During Period, Shares, Issued for Services (in shares) License Agreement Terms [Member] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity us-gaap_CashUninsuredAmount Cash, Uninsured Amount Issuance of stock for cash Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Effect of Covid 19 Pandemic [Text Block] The entire disclosure for effects of COVID-19 pandemic. Exercised, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights exercised during period. Cancelled or expired, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights cancelled during period. Accumulated deficit Research and development Changes in operating assets and liabilities: us-gaap_StockholdersEquity Total stockholders’ equity Balance Balance us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] Class of Stock [Axis] gnpx_LicensingFeeAmount Licensing Fee, Amount The amount of the agreed upon licensing fee. License Agreement [Member] An agreement where another party is permitted the right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark. Subsequent Event Type [Axis] Subsequent Event Type [Domain] gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent Royalty Percent, Licensed Technology Covered by Patent The percent of net sales of licensed technology covered by patents to be earned as royalty. Supplies The amount of research and development assets classified as noncurrent. gnpx_AnnualMaintenanceFeeAfterYearThreeAmount Annual Maintenance Fee, After Year Three, Amount The annual maintenance fee after the third year of an agreement. gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount Annual Maintenance Fee, First Three Years, Amount The amount of annual maintenance fees for the first three years of an agreement. Subsequent Events [Text Block] Security deposits University of Pittsburgh [Member] Information pertaining to the University of Pittsburgh. gnpx_ShareOfNonroyaltySublicenseIncomePercent Share of Non-Royalty Sublicense Income, Percent The share of non-royalty sublicense income, represented as a percent, to be received as part of an agreement. gnpx_AnnualRoyaltyPaymentPerYearMinimum Annual Royalty Payment Per Year, Minimum The minimum amount of royalty payment to be received each year. Dosing of First Human Patient in a Phase I Clinical Trial [Member] The scenario of a dosing of first human patient in a Phase I clinical trial. gnpx_MilestonePayment Milestone Payment The amount of a payment to be received upon achievement of an agreed upon milestone. EX-101.PRE 9 gnpx-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2022
May 10, 2022
Document Information [Line Items]    
Entity Central Index Key 0001595248  
Entity Registrant Name Genprex, Inc.  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-38244  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 90-0772347  
Entity Address, Address Line One 3300 Bee Cave Road, #650-227  
Entity Address, City or Town Austin  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 78746  
City Area Code 512  
Local Phone Number 537-7997  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol GNPX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   47,898,351
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Balance Sheets (Current Period Unaudited) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 34,555,337 $ 38,628,876
Accounts receivable 32,171 0
Prepaid expenses and other 1,115,601 511,348
Total current assets 35,703,109 39,140,224
Property and equipment, net 41,878 48,608
Other assets:    
Security deposits 10,000 8,691
Supplies 3,010,243 3,022,403
Intellectual property, net 644,201 642,360
Total other assets 3,664,444 3,673,454
Total assets 39,409,431 42,862,286
Current liabilities:    
Accounts payables 1,252,978 973,195
Other current liabilities 1,131,839 612,100
Total current liabilities 2,384,817 1,585,295
Stockholders’ equity:    
Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock $0.001 par value: 200,000,000 shares authorized; 47,879,708 and 47,874,708 shares issued and outstanding at March 31, 2022, and December 31, 2021, respectively 47,879 47,874
Additional paid-in capital 120,717,072 119,246,970
Accumulated deficit (83,740,337) (78,017,853)
Total stockholders’ equity 37,024,614 41,276,991
Total liabilities and stockholders’ equity $ 39,409,431 $ 42,862,286
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued (in shares) 47,879,708 47,874,708
Common stock, shares outstanding (in shares) 47,879,708 47,874,708
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues $ 0 $ 0
Cost and expenses:    
Depreciation 6,730 6,242
Research and development 1,860,837 2,169,143
General and administrative 3,855,796 4,316,310
Total costs and expenses 5,723,363 6,491,695
Operating loss (5,723,363) (6,491,695)
Interest income 879 1,982
Net loss $ (5,722,484) $ (6,489,713)
Net loss per share—basic and diluted (in dollars per share) $ (0.12) $ (0.14)
Weighted average number of common shares— basic and diluted (in shares) 47,879,597 45,546,106
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2020 43,117,681      
Balance at Dec. 31, 2020 $ 43,118 $ 89,295,601 $ (58,422,229) $ 30,916,490
Issuance of stock for cash (in shares) 4,192,139      
Issuance of stock for cash $ 4,192 25,320,138 0 25,324,330
Issuance of stock for services (in shares) 5,000      
Issuance of stock for services $ 5 20,645 0 20,650
Share based compensation 0 651,088 0 651,088
Net loss $ 0 0 (6,489,713) (6,489,713)
Balance (in shares) at Mar. 31, 2021 47,314,820      
Balance at Mar. 31, 2021 $ 47,315 115,287,472 (64,911,942) 50,422,845
Balance (in shares) at Dec. 31, 2020 43,117,681      
Balance at Dec. 31, 2020 $ 43,118 89,295,601 (58,422,229) $ 30,916,490
Issuance of stock for services (in shares)       86,138
Issuance of stock for services       $ 156,045
Balance (in shares) at Dec. 31, 2021 47,874,708      
Balance at Dec. 31, 2021 $ 47,874 119,246,970 (78,017,853) 41,276,991
Issuance of stock for cash (in shares) 0      
Issuance of stock for cash $ 0 0 0 $ 0
Issuance of stock for services (in shares) 5,000     5,000
Issuance of stock for services $ 5 17,495 0 $ 17,500
Share based compensation 0 1,452,607 0 1,452,607
Net loss $ 0 0 (5,722,484) (5,722,484)
Balance (in shares) at Mar. 31, 2022 47,879,708      
Balance at Mar. 31, 2022 $ 47,879 $ 120,717,072 $ (83,740,337) $ 37,024,614
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (5,722,484) $ (6,489,713)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 6,730 6,242
Share based compensation 1,470,107 671,738
Changes in operating assets and liabilities:    
Accounts receivable (32,171) 0
Prepaid expenses and other (605,561) 187,282
Accounts payable 279,783 146,493
Other current liabilities 519,739 12,676
Net cash used in operating activities (4,083,857) (5,465,282)
Cash flows from investing activities:    
Additions to property and equipment 0 (91,701)
Additions to intellectual property (1,841) (9,071)
Reductions (additions) to research and development supplies 12,160 (9,258)
Net cash provided (used) by investing activities 10,319 (110,030)
Cash flows from financing activities:    
Proceeds from issuances of stock 0 25,324,330
Net cash provided by financing activities 0 25,324,330
Net decrease (increase) in cash and cash equivalents (4,073,539) 19,749,018
Cash and cash equivalents, beginning of period 38,628,876 27,319,685
Cash and cash equivalents, end of period $ 34,555,337 $ 47,068,703
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Note 1 - Description of Business and Basis of Presentation
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 - Description of Business and Basis of Presentation

 

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.  Our oncology platform utilizes our non-viral ONCOPREX™ Nanoparticle Delivery System.  Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells.  Our diabetes technology is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

 

Oncology Platform

 

Our lead oncology drug candidate, REQORSA™ Immunogene Therapy, also sometimes referred to as GPX-001, initially is being developed in combination with top selling cancer drugs to treat Non-Small Cell Lung Cancer (“NSCLC”) and Small Cell Lung Cancer (“SCLC”). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA also has been shown to block mechanisms that create drug resistance and to be complementary with targeted drugs and immunotherapies.  We believe REQORSA’s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, who are not benefitting from current therapies.    

 

We currently are enrolling and treating patients in two Phase 1/2 clinical trials in NSCLC, our Acclaim-1 and Acclaim-2 clinical trials. The Acclaim-1 clinical trial (“Acclaim-1") is using a combination of REQORSA with AstraZeneca PLC’s Tagrisso® in patients with late-stage NSCLC with activating epidermal growth factor receptor ("EGFR") mutations, whose disease progressed after treatment with Tagrisso. The first patient was dosed in Acclaim-1 in February 2022. We expect the Phase 1 portion of Acclaim-1 to be completed by year end 2022. The Acclaim-2 clinical trial (“Acclaim-2”) is using a combination of REQORSA with Merck & Co.’s Keytruda® in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda. The first patient was dosed in Acclaim-2 in April 2022. We expect to complete the Phase 1 portion of Acclaim-2 by the end of the first quarter of 2023.

 

The Food and Drug Administration (“FDA”) has granted two Fast Track Designations, one for use of REQORSA in the patient population targeted in each of these trials. 

 

The TUSC2 gene is one of a series of genes whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").  We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of several cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates.

 

Diabetes Gene Therapy

 

In diabetes, we are developing a gene therapy that is exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) for the treatment of Type 1 and Type 2 diabetes. This potential treatment is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. The therapy utilizes a procedure in which an adeno-associated virus vector delivers Pdx1 and MafA genes to the pancreas. Our diabetes product candidate is currently being evaluated in preclinical studies at the University of Pittsburgh.

 

Capital Requirements, Liquidity and Going Concern Considerations

 

Our unaudited condensed financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying unaudited condensed financial statements, we have sustained substantial losses from operations since inception and have no current source of revenue. In addition, we have used, rather than provided, cash in our operations. We expect to continue to incur significant expenditures to further clinical trials for the commercial development of our product candidates.

 

Management recognizes that we must obtain additional capital resources to successfully commercialize our product candidates. To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, no assurances can be given that we will be successful in raising additional capital. If we are not able to timely and successfully raise additional capital, the timing of our clinical trials, financial condition and results of operations may be materially and adversely affected. These condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities.

 

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Note 2 - Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

Note 2 - Summary of Significant Accounting Policies

 

The Company’s unaudited condensed financial statements have been prepared in accordance with GAAP. However, they do not include all the information and footnotes required by GAAP for complete financial statements. In our opinion, the unaudited condensed financial statements include all adjustments (consisting of normal recurring accruals) necessary to make the unaudited condensed financial statements not misleading. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2022. For more complete financial information, these unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2021, included in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2022. A summary of our significant accounting policies consistently applied in the preparation of the accompanying unaudited condensed financial statements follows.

 

Capital Stock

 

The Company has the authority to issue up to 210,000,000 shares of stock consisting of 200,000,000 shares of common stock at a par value of $0.001 per share and 10,000,000 shares of preferred stock at a par value of $0.001 per share.

 

Use of Estimates

 

The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

We consider all highly liquid short-term investments with an initial maturity of three months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have cash equivalents in a money market account and had $34,178,486 and $38,392,886 in excess of FDIC insured limits of $250,000 at March 31, 2022 and December 31, 2021, respectively.

 

Fair Value of Financial Instruments

 

The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.

 

Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC 820’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC 820 classifies these inputs into the following hierarchy:

 

Level 1: Quoted prices for identical instruments in active markets.

 

Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

Level 3: Instruments with primarily unobservable value drivers.

 

Property and Equipment

 

Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.

 

Research and Development Costs

 

Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase 1/2 clinical trials and are expensed as incurred. Materials produced to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or clinical activities, or have spoiled.

 

Research and development supplies purchased and capitalized for future use were $3,010,243 and $3,022,403 at March 31, 2022 and December 31, 2021, respectively.

 

Intellectual Property

 

Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.

 

Accounting for Stock-Based Compensation

 

We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.

 

Long-Lived Assets

 

We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows. During the three months ended March 31, 2022, and the year ended December 31, 2021, there were no deemed impairments of our long-lived assets.

 

Recent Accounting Developments

 

Accounting pronouncements issued but not effective until after March 31, 2022, are not expected to have a significant effect on our financial condition, results of operations, or cash flows.

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Note 3 - Intellectual Property
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]

 

Note 3 - Intellectual Property

 

On February 11, 2020, we entered into an exclusive license agreement with the University of Pittsburgh for patented gene therapy technologies relating to the potential treatment of type 1 and type 2 diabetes. 

 

On May 4, 2020, we entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson relating to a portfolio of 16 patent applications and related technology for the treatment of cancer using the Company’s lead drug candidate, REQORSA, and immunotherapies. 

 

We own or have exclusive license agreements on 18 issued patents and 18 pending patent applications worldwide for technologies developed in-house or by researchers at the National Cancer Institute, MD Anderson, the University of Texas Southwestern Medical Center, and the University of Pittsburgh. These patents comprise various therapeutic, diagnostic, technical and processing claims. These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Equity
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

Note 4 - Equity

 

Registered Direct Offerings

 

On February 10, 2021, the Company completed a registered direct offering in which the Company sold to investors an aggregate of 4,000,000 shares of the Company's common stock at $6.25 per share. The Company received net proceeds of approximately $23.2 million after commissions and expenses.

 

Stock Issuances

 

During the three months ended March 31, 2022, we issued (i) 5,000 shares of common stock for services provided to us valued at $17,500 to the Chairman of our Scientific Advisory Board.

 

During the year ended December 31, 2021, we issued (i) 670,889 shares of common stock upon the exercise of options for cash proceeds of $677,912, and (ii) 86,138 shares of common stock for services provided to us valued at $156,045 to the Chairman of our Scientific Advisory Board and a consultant.

 

Preferred Stock

 

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, none of which are outstanding at March 31, 2022.

 

Common Stock

 

The Company is authorized to issue 200,000,000 shares of common stock with a par value of $0.001 per share, all of which are voting common stock. There were 47,879,708 shares of the Company's common stock outstanding at March 31, 2022.

 

Common Stock Purchase Warrants

 

Common stock purchase warrant activity for the period and year ended March 31, 2022, and December 31, 2021, respectively, is as follows:

 

  

Number of

  

Weighted Average

 
  

Warrants

  

Exercise Price

 

Outstanding at January 1, 2021

  2,154,747  $4.37 

Issued

  50,000   5.29 

Cancelled or expired

      

Exercised

      

Outstanding at December 31, 2021

  2,204,747  $4.39 

Issued

      

Cancelled or expired

      

Exercised

      

Outstanding at March 31, 2022

  2,204,747  $4.39 

Vested or expected to vest at March 31, 2022

      

Exercisable at March 31, 2022

  1,971,412  $4.62 

 

The Company did not issue warrants or record any share-based compensation associated with vesting of warrants during the three-month period ended March 31, 2022

 

In the year ended  December 31, 2021, the Company issued (i) a warrant to purchase up to 25,000 shares of common stock to a service provider at an exercise price of $7.22 per share, the fair market value of a share of common stock on the date of issuance and (ii) a warrant to purchase up to 25,000 shares of common stock to a service provider at an exercise price of $3.36 per share, the fair market value of a share of common stock on the date of issuance. During the year ended  December 31, 2021, we recorded share-based compensation of $200,282 associated with the vesting of warrants. 

 

On January 29, 2018, the Company entered into an agreement with a consultant whereby the Company agreed to grant warrants to purchase up to 6,000 shares of the Company's common stock at an exercise price of $5.00 per share in consideration of services valued at $30,000 provided to the Company. At March 31, 2022, the Company has not issued these warrants.

 

2018 Equity Incentive Plan

 

The Company’s board of directors and stockholders have approved and adopted the Company’s 2018 Equity Incentive Plan (“2018 Plan”), which became effective on the completion of the IPO on April 3, 2018. The 2018 Plan provides for the grant of incentive stock options that are intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended (“ISOs”), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and performance-based cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to the Company’s non-employee directors and consultants.

 

A total of 4,160,000 shares of common stock were initially available under the 2018 Plan, plus a number of shares of common stock (not to exceed 2,628,749 shares) subject to outstanding awards under our 2009 Equity Incentive Plan (the “2009 Plan”) as of the IPO that expire, are forfeited or otherwise terminate or that are used to cover the exercise price or applicable tax withholdings. No further grants will be made under the 2009 Plan.

 

In addition, the number of shares of common stock reserved for issuance under the 2018 Plan automatically increase on January 1 of each year, since  January 1, 2019, by 5% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our Board or a committee appointed to administer the 2018 Plan.

 

On  January 1, 2021, and 2022, the number of shares of common stock reserved for issuance under the 2018 Plan was increased by an aggregate of 2,155,884 and 2,393,735 shares, respectively. As of March 31, 2022, a total of 1,103,523 shares of common stock remains available for issuance under the 2018 Plan.

 

2018 Employee Stock Purchase Plan

 

The Company’s board of directors and stockholders approved and adopted the Company’s 2018 Employee Stock Purchase Plan (“ESPP”), which became effective on April 3, 2018. The ESPP has not yet been utilized as a benefit available to our employees. The ESPP authorizes the issuance of 208,500 shares of the Company’s common stock pursuant to purchase rights that may be granted to our eligible employees. The number of shares of common stock reserved for issuance under the ESPP is automatically increased on January 1 of each calendar year, beginning on January 1, 2019, by 2% of the total number of shares of the Company's common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the administrator of the ESPP. The administrator of the ESPP determined not to increase the number of shares reserved for issuance under the ESPP on  January 1, 2022.

 

Stock Options

 

As of March 31, 2022, the Company had outstanding stock options to purchase 10,961,363 shares of common stock that have been granted to various executives, employees, directors, and independent contractors. These options vest immediately or over periods ranging from 12 to 48 months, are exercisable for a period of up to ten years, and enable the holders to purchase shares of our common stock at exercise prices ranging from $0.015 to $9.80 per share. The per-share fair values of these options range from $0.015 to $7.93, based on Black-Scholes-Merton pricing models with the following assumptions:

 

Expected term (in years):

  10 

Risk-free rate:

  

0.07% – 2.63%

 

Volatility:

  

75.98% – 88.38%

 

Dividend yield:

  

0%

 

 

During the three-month period ended  March 31, 2022, the Company (i) granted stock options to purchase an aggregate of 2,404,562 shares of the Company's common stock with exercise prices ranging from $2.00 to $3.50 per share to executives and employees, and (ii) cancelled options to purchase 17,500 shares of common stock at an exercise price of $2.00 per share in connection with the termination of employment of an employee. 

 

In the year ended  December 31, 2021, the Company (i) granted stock options to purchase an aggregate of 2,519,628 shares of the Company's common stock with exercise prices ranging from $2.72 to $7.22 per share to executives, employees, board members, and consultants, (ii) cancelled options to purchase 118,507 shares of common stock with exercise prices ranging from $1.45 to $7.22 per share in connection with the termination of employment of employees, and (iii) issued 670,889 shares of the Company's common stock upon the exercise of options held by consultants, a former board member, and a former executive, with exercise prices ranging from $0.015 to $2.15 per share.

 

The weighted average remaining contractual term for the outstanding options at  March 31, 2022 and  December 31, 2021 is 7.61 and 7.24 years, respectively.
 

Stock option activity for the three months ended March 31, 2022, and year ended  December 31, 2021 is as follows:

 

  

Number of

  

Weighted Average

 
  

Shares

  

Exercise Price

 

Outstanding at January 1, 2021

  6,844,069  $2.81 

Options granted

  2,519,628   4.26 

Options exercised

  (670,889)  1.01 

Options expired

  (118,507)  3.00 

Outstanding at December 31, 2021

  8,574,301  $3.35 

Options granted

  2,404,562   2.30 

Options exercised

      

Options expired or cancelled

  (17,500)  2.00 

Outstanding at March 31, 2022

  10,961,363  $3.13 

Vested or expected to vest at March 31, 2022

  605,648   4.45 

Exercisable at March 31, 2022

  5,981,155  $3.20 

 

Share-Based Compensation

 

For the three months ended March 31, 2022, the Company's total share-based compensation was approximately $1.5 million, nearly all of which represents the vesting of options issued to executives, employees, and service providers. As of  March 31, 2022, the Company’s total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, employees, board members, and service providers and not yet recognized was approximately $10.6 million. The Company expects to record this stock-based compensation expense over the next three years using a graded vesting method. As of March 31, 2022, the weighted average term over which these expenses are expected to be recognized is 2.06 years. 

 

As of March 31, 2022, there are no performance-based stock option awards outstanding and one performance-based warrant outstanding issued to a service provider. The Company’s total compensation cost related to the non-vested performance-based warrant not yet recognized was approximately $300,000. The entirety of this warrant may be recognized and recorded upon the achievement of certain milestones.

 

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Note 5 - Related Party Transactions
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

Note 5 - Related Party Transactions

 

Introgen Research Institute

 

Introgen Research Institute (“IRI”) is a Texas-based technology company formed by Rodney Varner, our President, Chief Executive Officer and Chairman of the Board of which Mr. Varner is the sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In April 2009, prior to Mr. Varner becoming an officer and director of our Company in August 2012, we entered into an Assignment and Collaboration Agreement with IRI, providing us with the exclusive right to commercialize a portfolio of intellectual property. This agreement was amended in 2011 to include additional sublicensing of additional intellectual property made available to IRI from MD Anderson.

 

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Note 6 - Commitments and Contingencies
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

Note 6 - Commitments and Contingencies

 

Leases

 

On April 16, 2018, the Company executed a space utilization agreement with the Board of Regents of the University of Texas System to establish and lease offices at the Dell Medical School in Austin, Texas. On March 23, 2021, the Company was informed by Dell Medical School that the University of Texas desired to use the space and not renew the space utilization agreement. The lease terminated on April 30, 2021, and our employees all currently work virtually while we evaluate future space needs post the COVID-19 pandemic. 

 

Commitments

 

MD Anderson Cancer Center

 

The Company entered into a clinical study agreement with the MD Anderson, to administer the Company’s Phase 1/2 clinical trial, combining REQORSA and Tarceva in Stage 4 lung cancer patients. The trial was expected to run through the end of 2018 with a projected total cost of approximately $2 million. Payments are due and payable when invoiced throughout the clinical trial period. The agreement may be terminated at any time. In 2020, the Company received Fast Track Designation ("FTD") from the FDA for its Acclaim-1 trial which combines REQORSA plus Tagrisso in patients with stage III or IV NSCLC with EGFR mutations that progressed after treatment with Tagrisso. Given the FTD and with Tagrisso now considered a new standard of care in the U.S. for NSCLC with an EGFR mutation, the Company is no longer enrolling patients in its ONC-002 study and, in June 2021, initiated its Acclaim-1 trial.

 

In July 2018, the Company entered into a two-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on the combination of REQORSA with an immunotherapy with a projected total cost of approximately $2 million. Payments are due and payable when invoiced throughout the period. The agreement may be terminated at any time. This agreement has been extended through May 2022.

 

In 2011, the Company agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated with certain technologies and intellectual property originally licensed to another party under a 1994 License Agreement with MD Anderson (“Original MD Anderson License Agreement”). These technologies and intellectual property were later sublicensed to IRI (the “IRI Sublicense”). The Company also agreed to pay royalties of 1% on sales of certain licensed products for a period of 21 years following the termination of the later of the Original MD Anderson License Agreement and the IRI Sublicense. The Company assumed patent prosecution costs and an annual minimum royalty of $20,000 payable to the National Institutes of Health.

 

On March 3, 2021, the Company entered into an amendment (the “MD License Amendment”) to the Patent and Technology License Agreement dated May 4, 2020, with MD Anderson. The MD License Amendment grants the Company a worldwide, exclusive, sublicensable license to an additional portfolio of six patents and one patent application and related technology for methods for treating cancer by administration of a TUSC2 therapy in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy. Pursuant to the MD License Amendment, the Company agreed to (i) pay annual maintenance fees ranging from the mid five figures to the low six figures, (ii) total milestone payments of $6,150,000, (iii) a one-time fee in the mid five figures and (iv) certain patent related expenses.

 

 

National Institutes of Health

 

Our $191,393 payment obligation to the National Institutes of Health (“NIH”) represented a current obligation, of which $15,393 of 2016 patent prosecution costs were paid in the fourth quarter of 2016 and $176,000 was included in accounts payable at December 31, 2016 (consisting of accrued annual royalties of $140,000 and patent costs of $36,000). During the first quarter of 2017, we modified the terms of our accrued royalty obligation to NIH. Under the modified agreement, NIH agreed to extinguish $120,000 of the accrued royalties payable to it in consideration of payment by us of (i) accrued patent costs of $36,000, (ii) a royalty payment of $20,000, and (iii) a contingent payment of $240,000, increasing by $20,000 per year starting in 2018, to be paid upon our receipt of FDA approval. The payments for the patent costs of $36,000 and royalties of $20,000 were paid during the second quarter of 2017.

 

As a result of our modified agreement with the NIH, we have recognized the exchange of the $120,000 fixed obligation for the $240,000 contingent obligation as a $120,000 reduction to intellectual property expense (classified within general and administrative expense) during the first quarter of 2017. The $240,000 contingent obligation, which increases annually by $20,000 and was $340,000 as of March 31, 2022, will be recognized when we obtain regulatory approval (the event that triggers the payment obligation).

 

University of Pittsburgh

 

Pursuant to the Exclusive License Agreement dated February 11, 2020 by and between the Company and the University of Pittsburgh, the Company agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the first three years and $40,000 for each subsequent year following the first anniversary of the agreement, (iii) royalties ranging from 1.5% to 3% of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the first commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) 20 years after the first commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.

 

Contingencies

 

From time to time, we may become subject to threatened and/or asserted claims arising in the ordinary course of our business. Management is not aware of any matters, either individually or in the aggregate, that are reasonably likely to have a material impact on our financial condition, results of operations or liquidity.

 

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Note 7 - Significant Events
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Effect of Covid 19 Pandemic [Text Block]

Note 7 - Significant Events

 

The COVID-19 pandemic continues to have a major impact in the U.S. and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines may result in continued impact from this pandemic in the future, which could adversely impact our operations. Through March 31, 2021, the Company had not experienced any material impact on its financial results or operations as a result of the COVID-19 pandemic. Beginning in June 2021, the Company experienced delays in engaging clinical sites as a result of a backlog of clinical trial protocols requiring review created by an accumulation of clinical trial protocols. The Company continues to closely monitor the impact of the COVID-19 pandemic on its business and workforce.

 

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Note 8 - Subsequent Events
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Subsequent Events [Text Block]

Note 8 - Subsequent Events

 

Share Issuance

On April 1, 2022, the Company issued 5,000 shares of its common stock to the Chairman of our Scientific Advisory Board in consideration for services.

 

Option Issuance

On April 18, 2022, the Company issued a stock option grant under the 2018 Equity Incentive Plan to purchase a total of 17,500 shares of common stock to a new employee at the fair market value of the common stock on the date of issuance. 

 

Warrant Exercise

On May 4, 2022, we issued 13,643 shares of common stock to a placement agent associated with our November 2019 registered direct offering pursuant to the cashless exercise of a warrant. The remaining balance of the warrant representing the right to purchase 10,291 shares of common stock was cancelled.

 

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Stockholders' Equity, Policy [Policy Text Block]

Capital Stock

 

The Company has the authority to issue up to 210,000,000 shares of stock consisting of 200,000,000 shares of common stock at a par value of $0.001 per share and 10,000,000 shares of preferred stock at a par value of $0.001 per share.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

We consider all highly liquid short-term investments with an initial maturity of three months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have cash equivalents in a money market account and had $34,178,486 and $38,392,886 in excess of FDIC insured limits of $250,000 at March 31, 2022 and December 31, 2021, respectively.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

 

The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.

 

Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC 820’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC 820 classifies these inputs into the following hierarchy:

 

Level 1: Quoted prices for identical instruments in active markets.

 

Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

Level 3: Instruments with primarily unobservable value drivers.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

 

Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase 1/2 clinical trials and are expensed as incurred. Materials produced to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or clinical activities, or have spoiled.

 

Research and development supplies purchased and capitalized for future use were $3,010,243 and $3,022,403 at March 31, 2022 and December 31, 2021, respectively.

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intellectual Property

 

Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.

Share-Based Payment Arrangement [Policy Text Block]

Accounting for Stock-Based Compensation

 

We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-Lived Assets

 

We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows. During the three months ended March 31, 2022, and the year ended December 31, 2021, there were no deemed impairments of our long-lived assets.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Developments

 

Accounting pronouncements issued but not effective until after March 31, 2022, are not expected to have a significant effect on our financial condition, results of operations, or cash flows.

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Equity (Tables)
3 Months Ended
Mar. 31, 2022
Notes Tables  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
  

Number of

  

Weighted Average

 
  

Warrants

  

Exercise Price

 

Outstanding at January 1, 2021

  2,154,747  $4.37 

Issued

  50,000   5.29 

Cancelled or expired

      

Exercised

      

Outstanding at December 31, 2021

  2,204,747  $4.39 

Issued

      

Cancelled or expired

      

Exercised

      

Outstanding at March 31, 2022

  2,204,747  $4.39 

Vested or expected to vest at March 31, 2022

      

Exercisable at March 31, 2022

  1,971,412  $4.62 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Expected term (in years):

  10 

Risk-free rate:

  

0.07% – 2.63%

 

Volatility:

  

75.98% – 88.38%

 

Dividend yield:

  

0%

 
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of

  

Weighted Average

 
  

Shares

  

Exercise Price

 

Outstanding at January 1, 2021

  6,844,069  $2.81 

Options granted

  2,519,628   4.26 

Options exercised

  (670,889)  1.01 

Options expired

  (118,507)  3.00 

Outstanding at December 31, 2021

  8,574,301  $3.35 

Options granted

  2,404,562   2.30 

Options exercised

      

Options expired or cancelled

  (17,500)  2.00 

Outstanding at March 31, 2022

  10,961,363  $3.13 

Vested or expected to vest at March 31, 2022

  605,648   4.45 

Exercisable at March 31, 2022

  5,981,155  $3.20 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Apr. 03, 2018
Mar. 31, 2018
Capital Stock, Shares Authorized (in shares)       210,000,000
Common Stock, Shares Authorized (in shares) 200,000,000 200,000,000 200,000,000 200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 $ 0.001 $ 0.001 $ 0.001
Preferred Stock, Shares Authorized (in shares) 10,000,000 10,000,000 10,000,000 10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) $ 0.01 $ 0.01 $ 0.001 $ 0.001
Cash, Uninsured Amount $ 34,178,486 $ 38,392,886    
Research and Development Assets, Current 3,010,243 3,022,403    
Impairment, Long-Lived Asset, Held-for-Use, Total $ 0 $ 0    
Minimum [Member]        
Property, Plant and Equipment, Useful Life (Year) 3 years      
Maximum [Member]        
Property, Plant and Equipment, Useful Life (Year) 5 years      
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Equity (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Jan. 01, 2022
Feb. 10, 2021
Jan. 01, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Apr. 03, 2018
Mar. 31, 2018
Jan. 29, 2018
Proceeds from Issuance of Common Stock       $ 0 $ 25,324,330          
Stock Issued During Period, Shares, Issued for Services (in shares)       5,000   86,138        
Stock Issued During Period, Value, Issued for Services       $ 17,500 $ 20,650 $ 156,045        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)       (0)   670,889        
Stock Issued During Period, Value, Stock Options Exercised           $ 677,912        
Preferred Stock, Shares Authorized (in shares)       10,000,000   10,000,000   10,000,000 10,000,000  
Preferred Stock, Par or Stated Value Per Share (in dollars per share)       $ 0.01   $ 0.01   $ 0.001 $ 0.001  
Preferred Stock, Shares Outstanding, Ending Balance (in shares)       0   0        
Common Stock, Shares Authorized (in shares)       200,000,000   200,000,000   200,000,000 200,000,000  
Common Stock, Par or Stated Value Per Share (in dollars per share)       $ 0.001   $ 0.001   $ 0.001 $ 0.001  
Common Stock, Shares, Outstanding, Ending Balance (in shares)       47,879,708   47,874,708        
Class of Warrant or Right, Issued in Period (in shares)       0   50,000        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)       $ 4.39   $ 4.39 $ 4.37      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)       10,961,363   8,574,301 6,844,069      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)       10 years            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)       $ 3.13   $ 3.35 $ 2.81      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)       2,404,562   2,519,628        
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)       $ 2.30   $ 4.26        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares)       17,500   118,507        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)       $ 2.00   $ 3.00        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)       7 years 7 months 9 days   7 years 2 months 26 days        
Class of Warrant or Right, Outstanding (in shares)       2,204,747   2,204,747 2,154,747      
Share-Based Payment Arrangement, Option [Member]                    
Share-Based Payment Arrangement, Expense       $ 1,500,000            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total       $ 10,600,000            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       2 years 21 days            
Performance Shares [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)       0            
Minimum [Member]                    
Shares Issued, Price Per Share (in dollars per share)           $ 0.015        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)       12 months            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)       $ 0.015            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)       0.015            
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)       $ 2.00   2.72        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)           1.45        
Maximum [Member]                    
Shares Issued, Price Per Share (in dollars per share)           2.15        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)       48 months            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)       $ 9.80            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)       7.93            
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)       $ 3.50   7.22        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)           $ 7.22        
The 2018 Equity Incentive Plan [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)       1,103,523       4,160,000    
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year               5.00%    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 2,393,735   2,155,884              
The 2009 Plan [Member]                    
Common Stock, Capital Shares Reserved for Future Issuance (in shares)               2,628,749    
The 2018 Employee Stock Purchase Plan [Member]                    
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year               2.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)               208,500    
Warrant [Member]                    
Share-Based Payment Arrangement, Expense       $ 0            
Bear Creek Capital Warrant One [Member]                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)           25,000        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)           $ 7.22        
Bear Creek Capital Warrant Two [Member]                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)           25,000        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)           $ 3.36        
Bear Creek Capital Warrants [Member]                    
Share-Based Payment Arrangement, Expense           $ 200,282        
Performance-based Warrant [Member]                    
Class of Warrant or Right, Outstanding (in shares)       1            
Warrant, Nonvested Award, Cost Not yet Recognized, Amount       $ 300,000            
FundAthena, Inc [Member] | Warrants Issued for Services [Member]                    
Class of Warrant or Right, Issued in Period (in shares)       0            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                   6,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)                   $ 5.00
Accounts Payable, Total                   $ 30,000
Registered Direct Offering [Member] | Investors [Member]                    
Stock Issued During Period, Shares, New Issues (in shares)   4,000,000                
Shares Issued, Price Per Share (in dollars per share)   $ 6.25                
Proceeds from Issuance of Common Stock   $ 23,200,000                
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Outstanding, number of warrants (in shares) 2,204,747 2,154,747
Outstanding, weighted average exercise price (in dollars per share) $ 4.39 $ 4.37
Issued, number of warrants (in shares) 0 50,000
Issued, weighted average exercise price (in dollars per share) $ 0 $ 5.29
Cancelled or expired, number of warrants (in shares) 0 0
Cancelled or expired, weighted average exercise price (in dollars per share) $ 0 $ 0
Exercised, number of warrants (in shares) 0 0
Exercised, weighted average exercise price (in dollars per share) $ 0 $ 0
Outstanding, number of warrants (in shares) 2,204,747 2,204,747
Outstanding, weighted average exercise price (in dollars per share) $ 4.39 $ 4.39
Vested or expected to vest, number of warrants (in shares) 0  
Vested or expected to vest, weighted average exercise price (in dollars per share) $ 0  
Exercisable, number of warrants (in shares) 1,971,412  
Exercisable, weighted average exercise price (in dollars per share) $ 4.62  
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Equity - Assumptions (Details)
3 Months Ended
Mar. 31, 2022
Expected term (in years): (Year) 10 years
Dividend yield: 0.00%
Minimum [Member]  
Risk-free rate: 0.07%
Volatility: 75.98%
Maximum [Member]  
Risk-free rate: 2.63%
Volatility: 88.38%
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Equity - Stock Option Activity (Details) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Outstanding, number of shares (in shares) 8,574,301 6,844,069
Outstanding, weighted average exercise price (in dollars per share) $ 3.35 $ 2.81
Options granted, number of shares (in shares) 2,404,562 2,519,628
Options granted, weighted average exercise price (in dollars per share) $ 2.30 $ 4.26
Options exercised, number of shares (in shares) 0 (670,889)
Options exercised, weighted average exercise price (in dollars per share) $ 0 $ 1.01
Options expired (in shares) (17,500) (118,507)
Options expired, weighted average exercise price (in dollars per share) $ 2.00 $ 3.00
Outstanding, number of shares (in shares) 10,961,363 8,574,301
Outstanding, weighted average exercise price (in dollars per share) $ 3.13 $ 3.35
Vested or expected to vest, number of shares (in shares) 605,648  
Vested or expected to vest, weighted average exercise price (in dollars per share) $ 4.45  
Exercisable, number of shares (in shares) 5,981,155  
Exercisable, weighted average exercise price (in dollars per share) $ 3.20  
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Note 6 - Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 31, 2018
Mar. 31, 2022
Mar. 31, 2021
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2009
Mar. 03, 2021
Feb. 11, 2020
Other Commitment, Total   $ 340,000                  
Payments to Acquire Intangible Assets   $ 1,841 $ 9,071                
License Agreement Terms [Member]                      
License Agreement Milestone Payment                   $ 6,150,000  
National Institute of Health [Member]                      
Royalty on Sales, Percentage                 1.00%    
Royalty Term (Year)                 21 years    
Royalty Payment, Annual Minimum                 $ 20,000    
Other Commitment, Total           $ 191,393   $ 191,393      
Legal Fees           15,393          
Accounts Payable, Other, Current           176,000   176,000      
Accrued Royalties, Current           $ 140,000   140,000      
Other Expenses, Total               $ 36,000      
Extinguishment of Debt, Amount         $ 120,000            
Accrued Patent Costs, Current         36,000            
Payments for Royalties       $ 20,000 20,000            
Payment for Contingent Consideration Liability, Operating Activities         240,000            
Contingent Payments Annual Increase         20,000            
Payments to Acquire Intangible Assets       $ 36,000              
Finite-Lived Intangible Assets, Period Increase (Decrease), Total         $ (120,000)            
Clinical Trial Agreement [Member] | MD Anderson [Member]                      
Long Term Contract, Estimated Cost             $ 2,000,000        
Research Agreement [Member] | MD Anderson [Member]                      
Long Term Contract, Estimated Cost $ 2,000,000                    
License Agreement [Member] | University of Pittsburgh [Member]                      
Licensing Fee, Amount                     $ 25,000
Annual Maintenance Fee, First Three Years, Amount                     25,000
Annual Maintenance Fee, After Year Three, Amount                     40,000
Annual Royalty Payment Per Year, Minimum                     $ 250,000
Share of Non-Royalty Sublicense Income, Percent                     20.00%
License Agreement [Member] | University of Pittsburgh [Member] | Dosing of First Human Patient in a Phase I Clinical Trial [Member]                      
Milestone Payment                     $ 3,975,000
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member]                      
Royalty Percent, Licensed Technology Covered by Patent                     1.50%
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member]                      
Royalty Percent, Licensed Technology Covered by Patent                     3.00%
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Note 8 - Subsequent Events (Details Textual) - shares
3 Months Ended 12 Months Ended
May 04, 2022
Apr. 18, 2022
Apr. 01, 2022
Mar. 31, 2022
Dec. 31, 2021
Stock Issued During Period, Shares, Issued for Services (in shares)       5,000 86,138
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)       2,404,562 2,519,628
Class of Warrant or Right, Cancelled During Period (in shares)       (0) (0)
Subsequent Event [Member]          
Stock Issued During Period, Shares, Issued for Services (in shares)     5,000    
Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares) 13,643        
Class of Warrant or Right, Cancelled During Period (in shares) 10,291        
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)   17,500      
XML 33 gnpx20220331_10q_htm.xml IDEA: XBRL DOCUMENT 0001595248 2022-01-01 2022-03-31 0001595248 2022-05-10 0001595248 2022-03-31 0001595248 2021-12-31 0001595248 2021-01-01 2021-03-31 0001595248 us-gaap:CommonStockMember 2020-12-31 0001595248 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001595248 us-gaap:RetainedEarningsMember 2020-12-31 0001595248 2020-12-31 0001595248 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001595248 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001595248 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001595248 us-gaap:CommonStockMember 2021-03-31 0001595248 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001595248 us-gaap:RetainedEarningsMember 2021-03-31 0001595248 2021-03-31 0001595248 us-gaap:CommonStockMember 2021-12-31 0001595248 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001595248 us-gaap:RetainedEarningsMember 2021-12-31 0001595248 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001595248 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001595248 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001595248 us-gaap:CommonStockMember 2022-03-31 0001595248 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001595248 us-gaap:RetainedEarningsMember 2022-03-31 0001595248 2018-03-31 0001595248 srt:MinimumMember 2022-01-01 2022-03-31 0001595248 srt:MaximumMember 2022-01-01 2022-03-31 0001595248 2021-01-01 2021-12-31 0001595248 gnpx:InvestorsMember gnpx:RegisteredDirectOfferingMember 2021-02-10 2021-02-10 0001595248 gnpx:InvestorsMember gnpx:RegisteredDirectOfferingMember 2021-02-10 0001595248 2018-04-03 0001595248 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001595248 gnpx:BearCreekCapitalWarrantOneMember 2021-12-31 0001595248 gnpx:BearCreekCapitalWarrantTwoMember 2021-12-31 0001595248 gnpx:BearCreekCapitalWarrantsMember 2021-01-01 2021-12-31 0001595248 gnpx:FundathenaIncMember gnpx:WarrantsIssuedForServicesMember 2018-01-29 0001595248 gnpx:FundathenaIncMember gnpx:WarrantsIssuedForServicesMember 2022-01-01 2022-03-31 0001595248 gnpx:The2018EquityIncentivePlanMember 2018-04-03 0001595248 gnpx:The2009PlanMember 2018-04-03 0001595248 gnpx:The2018EquityIncentivePlanMember 2021-01-01 2021-01-01 0001595248 gnpx:The2018EquityIncentivePlanMember 2022-01-01 2022-01-01 0001595248 gnpx:The2018EquityIncentivePlanMember 2022-03-31 0001595248 gnpx:The2018EmployeeStockPurchasePlanMember 2018-04-03 0001595248 srt:MinimumMember 2022-03-31 0001595248 srt:MaximumMember 2022-03-31 0001595248 srt:MinimumMember 2021-01-01 2021-12-31 0001595248 srt:MaximumMember 2021-01-01 2021-12-31 0001595248 srt:MinimumMember 2021-12-31 0001595248 srt:MaximumMember 2021-12-31 0001595248 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001595248 us-gaap:EmployeeStockOptionMember 2022-03-31 0001595248 us-gaap:PerformanceSharesMember 2022-03-31 0001595248 gnpx:PerformancebasedWarrantMember 2022-03-31 0001595248 gnpx:MdAndersonMember gnpx:ClinicalTrialAgreementMember 2018-07-01 2018-12-31 0001595248 gnpx:MdAndersonMember gnpx:ResearchAgreementMember 2018-07-01 2018-07-31 0001595248 gnpx:NationalInstituteOfHealthMember 2009-12-31 0001595248 gnpx:NationalInstituteOfHealthMember 2009-01-01 2009-12-31 0001595248 us-gaap:LicenseAgreementTermsMember 2021-03-03 0001595248 gnpx:NationalInstituteOfHealthMember 2016-12-31 0001595248 gnpx:NationalInstituteOfHealthMember 2016-10-01 2016-12-31 0001595248 gnpx:NationalInstituteOfHealthMember 2016-01-01 2016-12-31 0001595248 gnpx:NationalInstituteOfHealthMember 2017-01-01 2017-03-31 0001595248 gnpx:NationalInstituteOfHealthMember 2017-03-31 0001595248 gnpx:NationalInstituteOfHealthMember 2017-04-01 2017-06-30 0001595248 gnpx:UniversityOfPittsburghMember gnpx:LicenseAgreementMember 2020-02-11 0001595248 gnpx:UniversityOfPittsburghMember srt:MinimumMember gnpx:LicenseAgreementMember 2020-02-11 0001595248 gnpx:UniversityOfPittsburghMember srt:MaximumMember gnpx:LicenseAgreementMember 2020-02-11 0001595248 gnpx:UniversityOfPittsburghMember gnpx:DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember gnpx:LicenseAgreementMember 2020-02-11 0001595248 us-gaap:SubsequentEventMember 2022-04-01 2022-04-01 0001595248 gnpx:The2018EquityIncentivePlanMember us-gaap:SubsequentEventMember 2022-04-18 2022-04-18 0001595248 us-gaap:SubsequentEventMember 2022-05-04 2022-05-04 shares thunderdome:item iso4217:USD iso4217:USD shares utr:Y pure utr:M 0001595248 Genprex, Inc. false --12-31 Q1 2022 0.01 0.01 10000000 10000000 0 0 0 0 0.001 0.001 200000000 200000000 47879708 47879708 47874708 47874708 P3Y P5Y 0 0 0 0 0 P10Y P10Y 10-Q true 2022-03-31 false 001-38244 DE 90-0772347 3300 Bee Cave Road, #650-227 Austin TX 78746 512 537-7997 Common Stock, par value $0.001 per share GNPX NASDAQ Yes Yes Non-accelerated Filer true true true false 47898351 34555337 38628876 32171 0 1115601 511348 35703109 39140224 41878 48608 10000 8691 3010243 3022403 644201 642360 3664444 3673454 39409431 42862286 1252978 973195 1131839 612100 2384817 1585295 0 0 47879 47874 120717072 119246970 -83740337 -78017853 37024614 41276991 39409431 42862286 0 0 6730 6242 1860837 2169143 3855796 4316310 5723363 6491695 -5723363 -6491695 879 1982 -5722484 -6489713 -0.12 -0.14 47879597 45546106 43117681 43118 89295601 -58422229 30916490 4192139 4192 25320138 0 25324330 5000 5 20645 0 20650 0 651088 0 651088 0 0 -6489713 -6489713 47314820 47315 115287472 -64911942 50422845 47874708 47874 119246970 -78017853 41276991 0 0 0 0 0 5000 5 17495 0 17500 0 1452607 0 1452607 0 0 -5722484 -5722484 47879708 47879 120717072 -83740337 37024614 -5722484 -6489713 6730 6242 1470107 671738 32171 -0 605561 -187282 279783 146493 519739 12676 -4083857 -5465282 -0 91701 1841 9071 -12160 9258 10319 -110030 0 25324330 0 25324330 -4073539 19749018 38628876 27319685 34555337 47068703 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; ">Note <em style="font: inherit;">1</em> - Description of Business and Basis of Presentation</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.  Our oncology platform utilizes our non-viral ONCOPREX™ Nanoparticle Delivery System.  Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells.  Our diabetes technology is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><span style="text-decoration: underline; ">Oncology Platform</span></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our lead oncology drug candidate, REQORSA™ Immunogene Therapy, also sometimes referred to as GPX-<em style="font: inherit;">001,</em> initially is being developed in combination with top selling cancer drugs to treat Non-Small Cell Lung Cancer (“NSCLC”) and Small Cell Lung Cancer (“SCLC”). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named <em style="font: inherit;">TUSC2.</em> REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA also has been shown to block mechanisms that create drug resistance and to be complementary with targeted drugs and immunotherapies.  We believe REQORSA’s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, who are <em style="font: inherit;">not</em> benefitting from current therapies.    </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We currently are enrolling and treating patients in <em style="font: inherit;">two</em> Phase <em style="font: inherit;">1/2</em> clinical trials in NSCLC, our Acclaim-<em style="font: inherit;">1</em> and Acclaim-<em style="font: inherit;">2</em> clinical trials. The Acclaim-<em style="font: inherit;">1</em> clinical trial (“Acclaim-<em style="font: inherit;">1"</em>) is using a combination of REQORSA with AstraZeneca PLC’s Tagrisso® in patients with late-stage NSCLC with activating epidermal growth factor receptor ("EGFR") mutations, whose disease progressed after treatment with Tagrisso. The <em style="font: inherit;">first</em> patient was dosed in Acclaim-<em style="font: inherit;">1</em> in <em style="font: inherit;"> February 2022. </em>We expect the Phase <em style="font: inherit;">1</em> portion of Acclaim-<em style="font: inherit;">1</em> to be completed by year end <em style="font: inherit;">2022.</em> The Acclaim-<em style="font: inherit;">2</em> clinical trial (“Acclaim-<em style="font: inherit;">2”</em>) is using a combination of REQORSA with Merck &amp; Co.’s Keytruda® in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda. The <em style="font: inherit;">first</em> patient was dosed in Acclaim-<em style="font: inherit;">2</em> in <em style="font: inherit;"> April 2022. </em>We expect to complete the Phase <em style="font: inherit;">1</em> portion of Acclaim-<em style="font: inherit;">2</em> by the end of the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Food and Drug Administration (“FDA”) has granted <em style="font: inherit;">two</em> Fast Track Designations, <em style="font: inherit;">one</em> for use of REQORSA in the patient population targeted in each of these trials. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The <em style="font: inherit;">TUSC2</em> gene is <em style="font: inherit;">one</em> of a series of genes whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").  We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of several cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><span style="text-decoration: underline; ">Diabetes Gene Therapy</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In diabetes, we are developing a gene therapy that is exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) for the treatment of Type <em style="font: inherit;">1</em> and Type <em style="font: inherit;">2</em> diabetes. This potential treatment is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. The therapy utilizes a procedure in which an adeno-associated virus vector delivers <em style="font: inherit;">Pdx1</em> and MafA genes to the pancreas. Our diabetes product candidate is currently being evaluated in preclinical studies at the University of Pittsburgh.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Capital Requirements, Liquidity and Going Concern Considerations</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our unaudited condensed financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying unaudited condensed financial statements, we have sustained substantial losses from operations since inception and have <em style="font: inherit;">no</em> current source of revenue. In addition, we have used, rather than provided, cash in our operations. We expect to continue to incur significant expenditures to further clinical trials for the commercial development of our product candidates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Management recognizes that we must obtain additional capital resources to successfully commercialize our product candidates. To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, <em style="font: inherit;">no</em> assurances can be given that we will be successful in raising additional capital. If we are <em style="font: inherit;">not</em> able to timely and successfully raise additional capital, the timing of our clinical trials, financial condition and results of operations <em style="font: inherit;"> may </em>be materially and adversely affected. These condensed financial statements do <em style="font: inherit;">not</em> include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; ">Note <em style="font: inherit;">2</em> - Summary of Significant Accounting Policies</span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company’s unaudited condensed financial statements have been prepared in accordance with GAAP. However, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In our opinion, the unaudited condensed financial statements include all adjustments (consisting of normal recurring accruals) necessary to make the unaudited condensed financial statements <em style="font: inherit;">not</em> misleading. Operating results for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022</em> are <em style="font: inherit;">not</em> necessarily indicative of the final results that <em style="font: inherit;"> may </em>be expected for the year ending <em style="font: inherit;"> December 31, 2022</em>. For more complete financial information, these unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements for the year ended <em style="font: inherit;"> December 31, 2021</em>, included in the Company's Annual Report on Form <em style="font: inherit;">10</em>-K filed with the U.S. Securities and Exchange Commission on <em style="font: inherit;"> March 30, 2022. </em>A summary of our significant accounting policies consistently applied in the preparation of the accompanying unaudited condensed financial statements follows.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Capital Stock</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has the authority to issue up to 210,000,000 shares of stock consisting of 200,000,000 shares of common stock at a par value of $0.001 per share and 10,000,000 shares of preferred stock at a par value of $0.001 per share.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Use of Estimates</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Cash and Cash Equivalents</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We consider all highly liquid short-term investments with an initial maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have cash equivalents in a money market account and had $34,178,486 and $38,392,886 in excess of FDIC insured limits of <em style="font: inherit;">$250,000</em> at <em style="font: inherit;"> March 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>, respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Fair Value of Financial Instruments</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Accounting Standards Codification ("ASC") <em style="font: inherit;">820,</em> Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC <em style="font: inherit;">820’s</em> valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC <em style="font: inherit;">820</em> classifies these inputs into the following hierarchy:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Level <em style="font: inherit;">1:</em> Quoted prices for identical instruments in active markets.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Level <em style="font: inherit;">2:</em> Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Level <em style="font: inherit;">3:</em> Instruments with primarily unobservable value drivers.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Property and Equipment</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:c84298517">three</span> to <span style="-sec-ix-hidden:c84298518">five</span> years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Research and Development Costs</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase <em style="font: inherit;">1/2</em> clinical trials and are expensed as incurred. Materials produced to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or clinical activities, or have spoiled.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development supplies purchased and capitalized for future use were $3,010,243 and $3,022,403 at <em style="font: inherit;"> March 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>, respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><i>Intellectual Property</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Accounting for Stock-Based Compensation</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Long-Lived Assets</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022</em>, and the year ended <em style="font: inherit;"> December 31, 2021</em>, there were <em style="font: inherit;">no</em> deemed impairments of our long-lived assets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Recent Accounting Developments</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Accounting pronouncements issued but <em style="font: inherit;">not</em> effective until after <em style="font: inherit;"> March 31, 2022</em>, are <em style="font: inherit;">not</em> expected to have a significant effect on our financial condition, results of operations, or cash flows.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Capital Stock</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has the authority to issue up to 210,000,000 shares of stock consisting of 200,000,000 shares of common stock at a par value of $0.001 per share and 10,000,000 shares of preferred stock at a par value of $0.001 per share.</p> 210000000 200000000 0.001 10000000 0.001 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Use of Estimates</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Cash and Cash Equivalents</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We consider all highly liquid short-term investments with an initial maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have cash equivalents in a money market account and had $34,178,486 and $38,392,886 in excess of FDIC insured limits of <em style="font: inherit;">$250,000</em> at <em style="font: inherit;"> March 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>, respectively.</p> 34178486 38392886 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Fair Value of Financial Instruments</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Accounting Standards Codification ("ASC") <em style="font: inherit;">820,</em> Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC <em style="font: inherit;">820’s</em> valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC <em style="font: inherit;">820</em> classifies these inputs into the following hierarchy:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Level <em style="font: inherit;">1:</em> Quoted prices for identical instruments in active markets.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Level <em style="font: inherit;">2:</em> Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Level <em style="font: inherit;">3:</em> Instruments with primarily unobservable value drivers.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Property and Equipment</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:c84298517">three</span> to <span style="-sec-ix-hidden:c84298518">five</span> years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Research and Development Costs</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase <em style="font: inherit;">1/2</em> clinical trials and are expensed as incurred. Materials produced to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or clinical activities, or have spoiled.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development supplies purchased and capitalized for future use were $3,010,243 and $3,022,403 at <em style="font: inherit;"> March 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>, respectively.</p> 3010243 3022403 <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><i>Intellectual Property</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Accounting for Stock-Based Compensation</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Long-Lived Assets</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022</em>, and the year ended <em style="font: inherit;"> December 31, 2021</em>, there were <em style="font: inherit;">no</em> deemed impairments of our long-lived assets.</p> 0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Recent Accounting Developments</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Accounting pronouncements issued but <em style="font: inherit;">not</em> effective until after <em style="font: inherit;"> March 31, 2022</em>, are <em style="font: inherit;">not</em> expected to have a significant effect on our financial condition, results of operations, or cash flows.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; ">Note <em style="font: inherit;">3</em> - Intellectual Property</span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">On <em style="font: inherit;"> February 11, 2020, </em>we entered into an exclusive license agreement with the University of Pittsburgh for patented gene therapy technologies relating to the potential treatment of type <em style="font: inherit;">1</em> and type <em style="font: inherit;">2</em> diabetes. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">On <em style="font: inherit;"> May 4, 2020, </em>we entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson relating to a portfolio of <em style="font: inherit;">16</em> patent applications and related technology for the treatment of cancer using the Company’s lead drug candidate, REQORSA, and immunotherapies. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We own or have exclusive license agreements on <em style="font: inherit;">18</em> issued patents and <em style="font: inherit;">18</em> pending patent applications worldwide for technologies developed in-house or by researchers at the National Cancer Institute, MD Anderson, the University of Texas Southwestern Medical Center, and the University of Pittsburgh. These patents comprise various therapeutic, diagnostic, technical and processing claims. These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; ">Note <em style="font: inherit;">4</em> - Equity</span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Registered Direct Offerings</i></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">On <em style="font: inherit;"> February 10, 2021, </em>the Company completed a registered direct offering in which the Company sold to investors an aggregate of 4,000,000 shares of the Company's common stock at $6.25 per share. The Company received net proceeds of approximately $23.2 million after commissions and expenses.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Stock Issuances</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022</em>, we issued (i) 5,000 shares of common stock for services provided to us valued at $17,500 to the Chairman of our Scientific Advisory Board.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2021</em>, we issued (i) 670,889 shares of common stock upon the exercise of options for cash proceeds of $677,912, and (ii) 86,138 shares of common stock for services provided to us valued at $156,045 to the Chairman of our Scientific Advisory Board and a consultant.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Preferred Stock</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, <span style="-sec-ix-hidden:c84298547">none</span> of which are outstanding at <em style="font: inherit;"> March 31, 2022</em>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Common Stock</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company is authorized to issue 200,000,000 shares of common stock with a par value of $0.001 per share, all of which are voting common stock. There were 47,879,708 shares of the Company's common stock outstanding at <em style="font: inherit;"> March 31, 2022</em>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Common Stock Purchase Warrants</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Common stock purchase warrant activity for the period and year ended <em style="font: inherit;"> March 31, 2022</em>, and <em style="font: inherit;"> December 31, 2021</em>, respectively, is as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,154,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Cancelled or expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,204,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Cancelled or expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,204,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Vested or expected to vest at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Exercisable at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">1,971,412</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">4.62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">The Company did <span style="-sec-ix-hidden:c84298552"><span style="-sec-ix-hidden:c84302549">not</span></span> issue warrants or record any share-based compensation associated with vesting of warrants during the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> March 31, 2022</em>. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">In the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company issued (i) a warrant to purchase up to 25,000 shares of common stock to a service provider at an exercise price of $7.22 per share, the fair market value of a share of common stock on the date of issuance and (ii) a warrant to purchase up to 25,000 shares of common stock to a service provider at an exercise price of $3.36 per share, the fair market value of a share of common stock on the date of issuance. During the year ended <em style="font: inherit;"> December 31, 2021, </em>we recorded share-based compensation of $200,282 associated with the vesting of warrants. </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <em style="font: inherit;"> January 29, 2018, </em>the Company entered into an agreement with a consultant whereby the Company agreed to grant warrants to purchase up to 6,000 shares of the Company's common stock at an exercise price of $5.00 per share in consideration of services valued at $30,000 provided to the Company. At <em style="font: inherit;"> March 31, 2022</em>, the Company has <span style="-sec-ix-hidden:c84298562">not</span> issued these warrants.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i><em style="font: inherit;">2018</em> Equity Incentive Plan</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company’s board of directors and stockholders have approved and adopted the Company’s <em style="font: inherit;">2018</em> Equity Incentive Plan (<em style="font: inherit;">“2018</em> Plan”), which became effective on the completion of the IPO on <em style="font: inherit;"> April 3, 2018. </em>The <em style="font: inherit;">2018</em> Plan provides for the grant of incentive stock options that are intended to qualify under Section <em style="font: inherit;">422</em> of the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended (“ISOs”), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and performance-based cash awards. ISOs <em style="font: inherit;"> may </em>be granted only to employees. All other awards <em style="font: inherit;"> may </em>be granted to employees, including officers, and to the Company’s non-employee directors and consultants.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">A total of 4,160,000 shares of common stock were initially available under the <em style="font: inherit;">2018</em> Plan, plus a number of shares of common stock (<em style="font: inherit;">not</em> to exceed 2,628,749 shares) subject to outstanding awards under our <em style="font: inherit;">2009</em> Equity Incentive Plan (the <em style="font: inherit;">“2009</em> Plan”) as of the IPO that expire, are forfeited or otherwise terminate or that are used to cover the exercise price or applicable tax withholdings. <em style="font: inherit;">No</em> further grants will be made under the <em style="font: inherit;">2009</em> Plan.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In addition, the number of shares of common stock reserved for issuance under the <em style="font: inherit;">2018</em> Plan automatically increase on <em style="font: inherit;"> January 1 </em>of each year, since <em style="font: inherit;"> January 1, 2019, </em>by 5% of the total number of shares of the Company’s common stock outstanding on <em style="font: inherit;"> December 31 </em>of the preceding calendar year, or a lesser number of shares determined by our Board or a committee appointed to administer the <em style="font: inherit;">2018</em> Plan.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> January 1, 2021, </em>and <em style="font: inherit;">2022,</em> the number of shares of common stock reserved for issuance under the <em style="font: inherit;">2018</em> Plan was increased by an aggregate of 2,155,884 and 2,393,735 shares, respectively. As of <em style="font: inherit;"> March 31, 2022</em>, a total of 1,103,523 shares of common stock remains available for issuance under the <em style="font: inherit;">2018</em> Plan.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i><em style="font: inherit;">2018</em> Employee Stock Purchase Plan</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company’s board of directors and stockholders approved and adopted the Company’s <em style="font: inherit;">2018</em> Employee Stock Purchase Plan (“ESPP”), which became effective on <em style="font: inherit;"> April 3, 2018. </em>The ESPP has <em style="font: inherit;">not</em> yet been utilized as a benefit available to our employees. The ESPP authorizes the issuance of 208,500 shares of the Company’s common stock pursuant to purchase rights that <em style="font: inherit;"> may </em>be granted to our eligible employees. The number of shares of common stock reserved for issuance under the ESPP is automatically increased on <em style="font: inherit;"> January 1 </em>of each calendar year, beginning on <em style="font: inherit;"> January 1, 2019, </em>by 2% of the total number of shares of the Company's common stock outstanding on <em style="font: inherit;"> December 31 </em>of the preceding calendar year, or a lesser number of shares determined by the administrator of the ESPP. The administrator of the ESPP determined <em style="font: inherit;">not</em> to increase the number of shares reserved for issuance under the ESPP on <em style="font: inherit;"> January 1, 2022</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="margin: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><span style="text-decoration: underline; "><i>Stock Options</i></span></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">As of <em style="font: inherit;"> March 31, 2022</em>, the Company had outstanding stock options to purchase 10,961,363 shares of common stock that have been granted to various executives, employees, directors, and independent contractors. These options vest immediately or over periods ranging from 12 to 48 months, are exercisable for a period of up to <span style="-sec-ix-hidden:c84298596">ten</span> years, and enable the holders to purchase shares of our common stock at exercise prices ranging from $0.015 to $9.80 per share. The per-share fair values of these options range from $0.015 to $7.93, based on Black-Scholes-Merton pricing models with the following assumptions:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Expected term (in years):</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="-sec-ix-hidden:c84298421">10</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free rate:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt">0.07% – 2.63%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Volatility:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt">75.98% – 88.38%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt">0%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> March 31, 2022</em>, the Company (i) granted stock options to purchase an aggregate of 2,404,562 shares of the Company's common stock with exercise prices ranging from $2.00 to $3.50 per share to executives and employees, and (ii) cancelled options to purchase 17,500 shares of common stock at an exercise price of $2.00 per share in connection with the termination of employment of an employee. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company (i) granted stock options to purchase an aggregate of 2,519,628 shares of the Company's common stock with exercise prices ranging from $2.72 to $7.22 per share to executives, employees, board members, and consultants, (ii) cancelled options to purchase 118,507 shares of common stock with exercise prices ranging from $1.45 to $7.22 per share in connection with the termination of employment of employees, and (iii) issued 670,889 shares of the Company's common stock upon the exercise of options held by consultants, a former board member, and a former executive, with exercise prices ranging from $0.015 to $2.15 per share.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <div style="font-size: 10pt;"> The weighted average remaining contractual term for the outstanding options at  <em style="font: inherit;"> March 31, 2022</em> and  <em style="font: inherit;"> December 31, 2021</em> is 7.61 and 7.24 years, respectively. </div> <div style="font-size: 10pt;">   </div> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">Stock option activity for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022</em>, and year ended <em style="font: inherit;"> December 31, 2021</em> is as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,844,069</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.81</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,519,628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.26</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(670,889</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(118,507</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,574,301</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,404,562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options expired or cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,961,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Vested or expected to vest at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">605,648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">4.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Exercisable at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">5,981,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">3.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Share-Based Compensation</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022</em>, the Company's total share-based compensation was approximately $1.5 million, nearly all of which represents the vesting of options issued to executives, employees, and service providers. As of <em style="font: inherit;"> March 31, 2022</em>, the Company’s total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, employees, board members, and service providers and <em style="font: inherit;">not</em> yet recognized was approximately $10.6 million. The Company expects to record this stock-based compensation expense over the next <em style="font: inherit;">three</em> years using a graded vesting method. As of <em style="font: inherit;"> March 31, 2022</em>, the weighted average term over which these expenses are expected to be recognized is 2.06 years. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As of <em style="font: inherit;"> March 31, 2022</em>, there are no performance-based stock option awards outstanding and one performance-based warrant outstanding issued to a service provider. The Company’s total compensation cost related to the non-vested performance-based warrant <em style="font: inherit;">not</em> yet recognized was approximately $300,000. The entirety of this warrant <em style="font: inherit;"> may </em>be recognized and recorded upon the achievement of certain milestones.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> 4000000 6.25 23200000 5000 17500 670889 677912 86138 156045 10000000 0.001 200000000 0.001 47879708 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,154,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Cancelled or expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,204,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Cancelled or expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,204,747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Vested or expected to vest at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Exercisable at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">1,971,412</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">4.62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> </tbody></table> 2154747 4.37 50000 5.29 -0 0 -0 0 2204747 4.39 0 0 -0 0 -0 0 2204747 4.39 0 0 1971412 4.62 25000 7.22 25000 3.36 200282 6000 5.00 30000 4160000 2628749 0.05 2155884 2393735 1103523 208500 0.02 10961363 P12M P48M 0.015 9.80 0.015 7.93 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Expected term (in years):</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="-sec-ix-hidden:c84298421">10</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free rate:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt">0.07% – 2.63%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Volatility:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt">75.98% – 88.38%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin-top: 0pt; margin-bottom: 0pt">0%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 0.0007 0.0263 0.7598 0.8838 0 2404562 2.00 3.50 17500 2.00 2519628 2.72 7.22 118507 1.45 7.22 670889 0.015 2.15 P7Y7M9D P7Y2M26D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,844,069</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.81</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,519,628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.26</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(670,889</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(118,507</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,574,301</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,404,562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13.7pt; text-align: left; text-indent: 0pt;">Options expired or cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,961,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Vested or expected to vest at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">605,648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">4.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Exercisable at March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">5,981,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">3.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> </tbody></table> 6844069 2.81 2519628 4.26 670889 1.01 118507 3.00 8574301 3.35 2404562 2.30 -0 0 17500 2.00 10961363 3.13 605648 4.45 5981155 3.20 1500000 10600000 P2Y21D 0 1 300000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; ">Note <em style="font: inherit;">5</em> - Related Party Transactions</span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Introgen Research Institute</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Introgen Research Institute (“IRI”) is a Texas-based technology company formed by Rodney Varner, our President, Chief Executive Officer and Chairman of the Board of which Mr. Varner is the sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In <em style="font: inherit;"> April 2009, </em>prior to Mr. Varner becoming an officer and director of our Company in <em style="font: inherit;"> August 2012, </em>we entered into an Assignment and Collaboration Agreement with IRI, providing us with the exclusive right to commercialize a portfolio of intellectual property. This agreement was amended in <em style="font: inherit;">2011</em> to include additional sublicensing of additional intellectual property made available to IRI from MD Anderson.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; ">Note <em style="font: inherit;">6</em> - Commitments and Contingencies</span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Leases</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">On <em style="font: inherit;"> April 16, 2018, </em>the Company executed a space utilization agreement with the Board of Regents of the University of Texas System to establish and lease offices at the Dell Medical School in Austin, Texas. On <em style="font: inherit;"> March 23, 2021, </em>the Company was informed by Dell Medical School that the University of Texas desired to use the space and <em style="font: inherit;">not</em> renew the space utilization agreement. The lease terminated on <em style="font: inherit;"> April 30, 2021, </em>and our employees all currently work virtually while we evaluate future space needs post the COVID-<em style="font: inherit;">19</em> pandemic. </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Commitments</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>MD Anderson Cancer Center</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company entered into a clinical study agreement with the MD Anderson, to administer the Company’s Phase <em style="font: inherit;">1/2</em> clinical trial, combining REQORSA and Tarceva in Stage <em style="font: inherit;">4</em> lung cancer patients. The trial was expected to run through the end of <em style="font: inherit;">2018</em> with a projected total cost of approximately $2 million. Payments are due and payable when invoiced throughout the clinical trial period. The agreement <em style="font: inherit;"> may </em>be terminated at any time. In <em style="font: inherit;">2020,</em> the Company received Fast Track Designation ("FTD") from the FDA for its Acclaim-<em style="font: inherit;">1</em> trial which combines REQORSA plus Tagrisso in patients with stage III or IV NSCLC with EGFR mutations that progressed after treatment with Tagrisso. Given the FTD and with Tagrisso now considered a new standard of care in the U.S. for NSCLC with an EGFR mutation, the Company is <em style="font: inherit;">no</em> longer enrolling patients in its ONC-<em style="font: inherit;">002</em> study and, in <em style="font: inherit;"> June 2021, </em>initiated its Acclaim-<em style="font: inherit;">1</em> trial.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> July 2018, </em>the Company entered into a <em style="font: inherit;">two</em>-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on the combination of REQORSA with an immunotherapy with a projected total cost of approximately $2 million. Payments are due and payable when invoiced throughout the period. The agreement <em style="font: inherit;"> may </em>be terminated at any time. This agreement has been extended through <em style="font: inherit;"> May 2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;">2011,</em> the Company agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated with certain technologies and intellectual property originally licensed to another party under a <em style="font: inherit;">1994</em> License Agreement with MD Anderson (“Original MD Anderson License Agreement”). These technologies and intellectual property were later sublicensed to IRI (the “IRI Sublicense”). The Company also agreed to pay royalties of 1% on sales of certain licensed products for a period of 21 years following the termination of the later of the Original MD Anderson License Agreement and the IRI Sublicense. The Company assumed patent prosecution costs and an annual minimum royalty of $20,000 payable to the National Institutes of Health.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 3, 2021, </em>the Company entered into an amendment (the “MD License Amendment”) to the Patent and Technology License Agreement dated <em style="font: inherit;"> May 4, 2020, </em>with MD Anderson. The MD License Amendment grants the Company a worldwide, exclusive, sublicensable license to an additional portfolio of <em style="font: inherit;">six</em> patents and <em style="font: inherit;">one</em> patent application and related technology for methods for treating cancer by administration of a <em style="font: inherit;">TUSC2</em> therapy in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to <em style="font: inherit;">TUSC2</em> therapy. Pursuant to the MD License Amendment, the Company agreed to (i) pay annual maintenance fees ranging from the mid <em style="font: inherit;">five</em> figures to the low <em style="font: inherit;">six</em> figures, (ii) total milestone payments of $6,150,000, (iii) a <em style="font: inherit;">one</em>-time fee in the mid <em style="font: inherit;">five</em> figures and (iv) certain patent related expenses.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><i>National Institutes of Health</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Our $191,393 payment obligation to the National Institutes of Health (“NIH”) represented a current obligation, of which $15,393 of <em style="font: inherit;">2016</em> patent prosecution costs were paid in the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2016</em> and $176,000 was included in accounts payable at <em style="font: inherit;"> December 31, 2016 (</em>consisting of accrued annual royalties of $140,000 and patent costs of $36,000). During the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2017,</em> we modified the terms of our accrued royalty obligation to NIH. Under the modified agreement, NIH agreed to extinguish $120,000 of the accrued royalties payable to it in consideration of payment by us of (i) accrued patent costs of $36,000, (ii) a royalty payment of $20,000, and (iii) a contingent payment of $240,000, increasing by $20,000 per year starting in <em style="font: inherit;">2018,</em> to be paid upon our receipt of FDA approval. The payments for the patent costs of $36,000 and royalties of $20,000 were paid during the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2017.</em></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">As a result of our modified agreement with the NIH, we have recognized the exchange of the <em style="font: inherit;">$120,000</em> fixed obligation for the <em style="font: inherit;">$240,000</em> contingent obligation as a $120,000 reduction to intellectual property expense (classified within general and administrative expense) during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2017.</em> The <em style="font: inherit;">$240,000</em> contingent obligation, which increases annually by <em style="font: inherit;">$20,000</em> and was $340,000 as of <em style="font: inherit;"> March 31, 2022</em>, will be recognized when we obtain regulatory approval (the event that triggers the payment obligation).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><i>University of Pittsburgh</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Pursuant to the Exclusive License Agreement dated <em style="font: inherit;"> February 11, 2020 </em>by and between the Company and the University of Pittsburgh, the Company agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> years and $40,000 for each subsequent year following the <em style="font: inherit;">first</em> anniversary of the agreement, (iii) royalties ranging from 1.5% to 3% of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the <em style="font: inherit;">first</em> commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) <em style="font: inherit;">20</em> years after the <em style="font: inherit;">first</em> commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Contingencies</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">From time to time, we <em style="font: inherit;"> may </em>become subject to threatened and/or asserted claims arising in the ordinary course of our business. Management is <em style="font: inherit;">not</em> aware of any matters, either individually or in the aggregate, that are reasonably likely to have a material impact on our financial condition, results of operations or liquidity.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> 2000000 2000000 0.01 P21Y 20000 6150000 191393 15393 176000 140000 36000 120000 36000 20000 240000 20000 36000 20000 -120000 340000 25000 25000 40000 0.015 0.03 250000 0.20 3975000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; ">Note <em style="font: inherit;">7</em> - Significant Events</span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">The COVID-<em style="font: inherit;">19</em> pandemic continues to have a major impact in the U.S. and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines <em style="font: inherit;"> may </em>result in continued impact from this pandemic in the future, which could adversely impact our operations. Through <em style="font: inherit;"> March 31, 2021, </em>the Company had <em style="font: inherit;">not</em> experienced any material impact on its financial results or operations as a result of the COVID-<em style="font: inherit;">19</em> pandemic. Beginning in <em style="font: inherit;"> June 2021, </em>the Company experienced delays in engaging clinical sites as a result of a backlog of clinical trial protocols requiring review created by an accumulation of clinical trial protocols. The Company continues to closely monitor the impact of the COVID-<em style="font: inherit;">19</em> pandemic on its business and workforce.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Note <em style="font: inherit;">8</em> - Subsequent Events</span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="text-decoration: underline; "><i>Share Issuance</i></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">On <em style="font: inherit;"> April 1, 2022, </em>the Company issued 5,000 shares of its common stock to the Chairman of our Scientific Advisory Board in consideration for services.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><i><span style="text-decoration: underline; ">Option Issuance</span></i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">On <em style="font: inherit;"> April 18, 2022, </em>the Company issued a stock option grant under the <em style="font: inherit;">2018</em> Equity Incentive Plan to purchase a total of 17,500 shares of common stock to a new employee at the fair market value of the common stock on the date of issuance. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><i><span style="text-decoration: underline; ">Warrant Exercise</span></i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">On <em style="font: inherit;"> May 4, 2022, </em>we issued 13,643 shares of common stock to a placement agent associated with our <em style="font: inherit;"> November 2019 </em>registered direct offering pursuant to the cashless exercise of a warrant. The remaining balance of the warrant representing the right to purchase 10,291 shares of common stock was cancelled.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"/> 5000 17500 13643 10291 EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 35 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 72 182 1 false 28 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.genprex.com/20220331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Balance Sheets (Current Period Unaudited) Sheet http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited Condensed Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited Condensed Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Description of Business and Basis of Presentation Sheet http://www.genprex.com/20220331/role/statement-note-1-description-of-business-and-basis-of-presentation Note 1 - Description of Business and Basis of Presentation Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Intellectual Property Sheet http://www.genprex.com/20220331/role/statement-note-3-intellectual-property Note 3 - Intellectual Property Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Equity Sheet http://www.genprex.com/20220331/role/statement-note-4-equity Note 4 - Equity Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Related Party Transactions Sheet http://www.genprex.com/20220331/role/statement-note-5-related-party-transactions Note 5 - Related Party Transactions Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies Note 6 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Significant Events Sheet http://www.genprex.com/20220331/role/statement-note-7-significant-events- Note 7 - Significant Events Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Subsequent Events Sheet http://www.genprex.com/20220331/role/statement-note-8-subsequent-events Note 8 - Subsequent Events Notes 14 false false R15.htm 014 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies 15 false false R16.htm 015 - Disclosure - Note 4 - Equity (Tables) Sheet http://www.genprex.com/20220331/role/statement-note-4-equity-tables Note 4 - Equity (Tables) Tables http://www.genprex.com/20220331/role/statement-note-4-equity 16 false false R17.htm 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details 17 false false R18.htm 017 - Disclosure - Note 4 - Equity (Details Textual) Sheet http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual Note 4 - Equity (Details Textual) Details http://www.genprex.com/20220331/role/statement-note-4-equity-tables 18 false false R19.htm 018 - Disclosure - Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) Sheet http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) Details 19 false false R20.htm 019 - Disclosure - Note 4 - Equity - Assumptions (Details) Sheet http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details Note 4 - Equity - Assumptions (Details) Details 20 false false R21.htm 020 - Disclosure - Note 4 - Equity - Stock Option Activity (Details) Sheet http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details Note 4 - Equity - Stock Option Activity (Details) Details 21 false false R22.htm 021 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) Sheet http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual Note 6 - Commitments and Contingencies (Details Textual) Details http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies 22 false false R23.htm 022 - Disclosure - Note 8 - Subsequent Events (Details Textual) Sheet http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual Note 8 - Subsequent Events (Details Textual) Details http://www.genprex.com/20220331/role/statement-note-8-subsequent-events 23 false false All Reports Book All Reports gnpx20220331_10q.htm ex_342874.htm ex_342875.htm ex_342876.htm gnpx-20220331.xsd gnpx-20220331_cal.xml gnpx-20220331_def.xml gnpx-20220331_lab.xml gnpx-20220331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 40 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "gnpx20220331_10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 72, "dts": { "calculationLink": { "local": [ "gnpx-20220331_cal.xml" ] }, "definitionLink": { "local": [ "gnpx-20220331_def.xml" ] }, "inline": { "local": [ "gnpx20220331_10q.htm" ] }, "labelLink": { "local": [ "gnpx-20220331_lab.xml" ] }, "presentationLink": { "local": [ "gnpx-20220331_pre.xml" ] }, "schema": { "local": [ "gnpx-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 263, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 23, "http://www.genprex.com/20220331": 2, "http://xbrl.sec.gov/dei/2022": 6, "total": 31 }, "keyCustom": 32, "keyStandard": 150, "memberCustom": 18, "memberStandard": 10, "nsprefix": "gnpx", "nsuri": "http://www.genprex.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.genprex.com/20220331/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Equity", "role": "http://www.genprex.com/20220331/role/statement-note-4-equity", "shortName": "Note 4 - Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Related Party Transactions", "role": "http://www.genprex.com/20220331/role/statement-note-5-related-party-transactions", "shortName": "Note 5 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Commitments and Contingencies", "role": "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "shortName": "Note 6 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "gnpx:EffectOfCovid19PandemicTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Significant Events", "role": "http://www.genprex.com/20220331/role/statement-note-7-significant-events-", "shortName": "Note 7 - Significant Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "gnpx:EffectOfCovid19PandemicTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Subsequent Events", "role": "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "shortName": "Note 8 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 4 - Equity (Tables)", "role": "http://www.genprex.com/20220331/role/statement-note-4-equity-tables", "shortName": "Note 4 - Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2018-03-31", "decimals": "INF", "first": true, "lang": null, "name": "gnpx:CapitalStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2018-03-31", "decimals": "INF", "first": true, "lang": null, "name": "gnpx:CapitalStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 4 - Equity (Details Textual)", "role": "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "shortName": "Note 4 - Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)", "role": "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "shortName": "Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "lang": null, "name": "gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Balance Sheets (Current Period Unaudited)", "role": "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited", "shortName": "Condensed Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 4 - Equity - Assumptions (Details)", "role": "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "shortName": "Note 4 - Equity - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 4 - Equity - Stock Option Activity (Details)", "role": "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details", "shortName": "Note 4 - Equity - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual)", "role": "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual", "shortName": "Note 6 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 8 - Subsequent Events (Details Textual)", "role": "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual", "shortName": "Note 8 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-04-01_2022-04-01_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Condensed Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Statements of Operations (Unaudited)", "role": "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)", "role": "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited", "shortName": "Condensed Statements of Changes in Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Statements of Cash Flows (Unaudited)", "role": "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Description of Business and Basis of Presentation", "role": "http://www.genprex.com/20220331/role/statement-note-1-description-of-business-and-basis-of-presentation", "shortName": "Note 1 - Description of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "role": "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Intellectual Property", "role": "http://www.genprex.com/20220331/role/statement-note-3-intellectual-property", "shortName": "Note 3 - Intellectual Property", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnpx20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 28, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited", "http://www.genprex.com/20220331/role/statement-document-and-entity-information", "http://www.genprex.com/20220331/role/statement-note-1-description-of-business-and-basis-of-presentation", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-3-intellectual-property", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-tables", "http://www.genprex.com/20220331/role/statement-note-5-related-party-transactions", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.genprex.com/20220331/role/statement-note-7-significant-events-", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual", "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited", "http://www.genprex.com/20220331/role/statement-document-and-entity-information", "http://www.genprex.com/20220331/role/statement-note-1-description-of-business-and-basis-of-presentation", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-3-intellectual-property", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-tables", "http://www.genprex.com/20220331/role/statement-note-5-related-party-transactions", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.genprex.com/20220331/role/statement-note-7-significant-events-", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual", "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "gnpx_AccruedPatentCostsCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued patent costs current.", "label": "gnpx_AccruedPatentCostsCurrent", "terseLabel": "Accrued Patent Costs, Current" } } }, "localname": "AccruedPatentCostsCurrent", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_AnnualMaintenanceFeeAfterYearThreeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The annual maintenance fee after the third year of an agreement.", "label": "gnpx_AnnualMaintenanceFeeAfterYearThreeAmount", "terseLabel": "Annual Maintenance Fee, After Year Three, Amount" } } }, "localname": "AnnualMaintenanceFeeAfterYearThreeAmount", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of annual maintenance fees for the first three years of an agreement.", "label": "gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount", "terseLabel": "Annual Maintenance Fee, First Three Years, Amount" } } }, "localname": "AnnualMaintenanceFeeFirstThreeYearsAmount", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_AnnualRoyaltyPaymentPerYearMinimum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of royalty payment to be received each year.", "label": "gnpx_AnnualRoyaltyPaymentPerYearMinimum", "terseLabel": "Annual Royalty Payment Per Year, Minimum" } } }, "localname": "AnnualRoyaltyPaymentPerYearMinimum", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_BearCreekCapitalWarrantOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Bear Creek Capital warrant one.", "label": "Bear Creek Capital Warrant One [Member]" } } }, "localname": "BearCreekCapitalWarrantOneMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_BearCreekCapitalWarrantTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Bear Creek Capital warrant two.", "label": "Bear Creek Capital Warrant Two [Member]" } } }, "localname": "BearCreekCapitalWarrantTwoMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_BearCreekCapitalWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Bear Creek Capital warrants.", "label": "Bear Creek Capital Warrants [Member]" } } }, "localname": "BearCreekCapitalWarrantsMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_CapitalStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital stock shares authorized.", "label": "gnpx_CapitalStockSharesAuthorized", "terseLabel": "Capital Stock, Shares Authorized (in shares)" } } }, "localname": "CapitalStockSharesAuthorized", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "gnpx_ClassOfWarrantOrRightCancelledDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights cancelled during period.", "label": "gnpx_ClassOfWarrantOrRightCancelledDuringPeriod", "negatedLabel": "Cancelled or expired, number of warrants (in shares)", "terseLabel": "Class of Warrant or Right, Cancelled During Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightCancelledDuringPeriod", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights cancelled during period.", "label": "Cancelled or expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "gnpx_ClassOfWarrantOrRightExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercisable.", "label": "Exercisable, number of warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisable", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "gnpx_ClassOfWarrantOrRightExercisableExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights exercisable.", "label": "gnpx_ClassOfWarrantOrRightExercisableExercisePrice", "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisableExercisePrice", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "gnpx_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during period.", "label": "gnpx_ClassOfWarrantOrRightExercisedDuringPeriod", "negatedLabel": "Exercised, number of warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights exercised during period.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights issued during period.", "label": "Issued, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "gnpx_ClassOfWarrantOrRightIssuedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights issued during period.", "label": "Issued, number of warrants (in shares)", "terseLabel": "Class of Warrant or Right, Issued in Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightIssuedInPeriod", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "gnpx_ClassOfWarrantOrRightVestedOrExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights vested or expected to vest.", "label": "gnpx_ClassOfWarrantOrRightVestedOrExpectedToVest", "terseLabel": "Vested or expected to vest, number of warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightVestedOrExpectedToVest", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "gnpx_ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of warrants or rights vested or expected to vest.", "label": "gnpx_ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice", "terseLabel": "Vested or expected to vest, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "gnpx_ClinicalTrialAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the clinical trial agreement.", "label": "Clinical Trial Agreement [Member]" } } }, "localname": "ClinicalTrialAgreementMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_ContingentPaymentsAnnualIncrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual increase in contingent payment.", "label": "gnpx_ContingentPaymentsAnnualIncrease", "terseLabel": "Contingent Payments Annual Increase" } } }, "localname": "ContingentPaymentsAnnualIncrease", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The scenario of a dosing of first human patient in a Phase I clinical trial.", "label": "Dosing of First Human Patient in a Phase I Clinical Trial [Member]" } } }, "localname": "DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_EffectOfCovid19PandemicTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for effects of COVID-19 pandemic.", "label": "Effect of Covid 19 Pandemic [Text Block]" } } }, "localname": "EffectOfCovid19PandemicTextBlock", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-7-significant-events-" ], "xbrltype": "textBlockItemType" }, "gnpx_FundathenaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent FundAthena, Inc.", "label": "FundAthena, Inc [Member]" } } }, "localname": "FundathenaIncMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_InvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the investors of the company.", "label": "Investors [Member]" } } }, "localname": "InvestorsMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An agreement where another party is permitted the right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_LicenseAgreementMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disclosure of milestone payments made for License Agreements.", "label": "gnpx_LicenseAgreementMilestonePayment", "terseLabel": "License Agreement Milestone Payment" } } }, "localname": "LicenseAgreementMilestonePayment", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_LicensingFeeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the agreed upon licensing fee.", "label": "gnpx_LicensingFeeAmount", "terseLabel": "Licensing Fee, Amount" } } }, "localname": "LicensingFeeAmount", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_LongTermContractEstimatedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated total cost of of long term contract.", "label": "gnpx_LongTermContractEstimatedCost", "terseLabel": "Long Term Contract, Estimated Cost" } } }, "localname": "LongTermContractEstimatedCost", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_MdAndersonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents MD Anderson.", "label": "MD Anderson [Member]" } } }, "localname": "MdAndersonMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_MilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of a payment to be received upon achievement of an agreed upon milestone.", "label": "gnpx_MilestonePayment", "terseLabel": "Milestone Payment" } } }, "localname": "MilestonePayment", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_NationalInstituteOfHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the national institute of health (NIH).", "label": "National Institute of Health [Member]" } } }, "localname": "NationalInstituteOfHealthMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.genprex.com/20220331", "xbrltype": "stringItemType" }, "gnpx_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.genprex.com/20220331", "xbrltype": "stringItemType" }, "gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies": { "auth_ref": [], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow or inflow for research and development supplies.", "label": "gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies", "negatedLabel": "Reductions (additions) to research and development supplies" } } }, "localname": "PaymentsForProceedsFromResearchAndDevelopmentSupplies", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "gnpx_PerformancebasedWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to performance-based warrant.", "label": "Performance-based Warrant [Member]" } } }, "localname": "PerformancebasedWarrantMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_RegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Registered Direct Offering.", "label": "Registered Direct Offering [Member]" } } }, "localname": "RegisteredDirectOfferingMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_ResearchAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the research agreement.", "label": "Research Agreement [Member]" } } }, "localname": "ResearchAgreementMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_ResearchAndDevelopmentAssetsCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research and development assets classified as current.", "label": "gnpx_ResearchAndDevelopmentAssetsCurrent", "terseLabel": "Research and Development Assets, Current" } } }, "localname": "ResearchAndDevelopmentAssetsCurrent", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_ResearchAndDevelopmentAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research and development assets classified as noncurrent.", "label": "Supplies" } } }, "localname": "ResearchAndDevelopmentAssetsNoncurrent", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "gnpx_RoyaltyOnSalesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of sales of royalty.", "label": "gnpx_RoyaltyOnSalesPercentage", "terseLabel": "Royalty on Sales, Percentage" } } }, "localname": "RoyaltyOnSalesPercentage", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "gnpx_RoyaltyPaymentAnnualMinimum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum of annual royalty payment.", "label": "gnpx_RoyaltyPaymentAnnualMinimum", "terseLabel": "Royalty Payment, Annual Minimum" } } }, "localname": "RoyaltyPaymentAnnualMinimum", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of net sales of licensed technology covered by patents to be earned as royalty.", "label": "gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent", "terseLabel": "Royalty Percent, Licensed Technology Covered by Patent" } } }, "localname": "RoyaltyPercentLicensedTechnologyCoveredByPatent", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "gnpx_RoyaltyTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terms of the royalty agreement, as a percentage of net sales of licensed technologies .", "label": "gnpx_RoyaltyTerms", "terseLabel": "Royalty Term (Year)" } } }, "localname": "RoyaltyTerms", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "durationItemType" }, "gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award percentage applied on outstanding shares of common stock for automatically increase on each year.", "label": "gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "percentItemType" }, "gnpx_ShareOfNonroyaltySublicenseIncomePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The share of non-royalty sublicense income, represented as a percent, to be received as part of an agreement.", "label": "gnpx_ShareOfNonroyaltySublicenseIncomePercent", "terseLabel": "Share of Non-Royalty Sublicense Income, Percent" } } }, "localname": "ShareOfNonroyaltySublicenseIncomePercent", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value of stock issued in shares for exercise of cashless warrants.", "label": "gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants", "terseLabel": "Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "gnpx_The2009PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2009 plan.", "label": "The 2009 Plan [Member]" } } }, "localname": "The2009PlanMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_The2018EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the 2018 employee stock purchase plan.", "label": "The 2018 Employee Stock Purchase Plan [Member]" } } }, "localname": "The2018EmployeeStockPurchasePlanMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_The2018EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the 2018 equity incentive plan.", "label": "The 2018 Equity Incentive Plan [Member]" } } }, "localname": "The2018EquityIncentivePlanMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_UniversityOfPittsburghMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the University of Pittsburgh.", "label": "University of Pittsburgh [Member]" } } }, "localname": "UniversityOfPittsburghMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested warrant.", "label": "gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount", "terseLabel": "Warrant, Nonvested Award, Cost Not yet Recognized, Amount" } } }, "localname": "WarrantNonvestedAwardCostNotYetRecognizedAmount", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "gnpx_WarrantsIssuedForServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrant issued fro services.", "label": "Warrants Issued for Services [Member]" } } }, "localname": "WarrantsIssuedForServicesMember", "nsuri": "http://www.genprex.com/20220331", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "gnpx_statement-statement-note-4-equity-assumptions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Equity - Assumptions (Details)" } } }, "localname": "statement-statement-note-4-equity-assumptions-details", "nsuri": "http://www.genprex.com/20220331", "xbrltype": "stringItemType" }, "gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)" } } }, "localname": "statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details", "nsuri": "http://www.genprex.com/20220331", "xbrltype": "stringItemType" }, "gnpx_statement-statement-note-4-equity-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Equity - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-4-equity-stock-option-activity-details", "nsuri": "http://www.genprex.com/20220331", "xbrltype": "stringItemType" }, "gnpx_statement-statement-note-4-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Equity" } } }, "localname": "statement-statement-note-4-equity-tables", "nsuri": "http://www.genprex.com/20220331", "xbrltype": "stringItemType" }, "gnpx_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.genprex.com/20220331", "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r24", "r26", "r56", "r57", "r142", "r147" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r125", "r126", "r127", "r128", "r141", "r146", "r165", "r167", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r279", "r280", "r289", "r290" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r125", "r126", "r127", "r128", "r141", "r146", "r165", "r167", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r279", "r280", "r289", "r290" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r120", "r125", "r126", "r127", "r128", "r141", "r146", "r164", "r165", "r167", "r198", "r199", "r200", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r279", "r280", "r289", "r290" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r120", "r125", "r126", "r127", "r128", "r141", "r146", "r164", "r165", "r167", "r198", "r199", "r200", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r279", "r280", "r289", "r290" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r25", "r26", "r56", "r57", "r142", "r147" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r67", "r72", "r124", "r166" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r67", "r72", "r124", "r166", "r249" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payables" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r266", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_AccountsPayableCurrentAndNoncurrent", "terseLabel": "Accounts Payable, Total" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "us-gaap_AccountsPayableOtherCurrent", "terseLabel": "Accounts Payable, Other, Current" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r105", "r106" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r6", "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedRoyaltiesCurrent", "terseLabel": "Accrued Royalties, Current" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r12", "r246" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r59", "r60", "r61", "r205", "r206", "r207", "r224" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r168", "r209", "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r55", "r92", "r95", "r100", "r108", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r218", "r220", "r229", "r244", "r246", "r264", "r271" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r17", "r55", "r108", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r218", "r220", "r229", "r244", "r246" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r193", "r194", "r197", "r198", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r7", "r49" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r43", "r49", "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r43", "r230" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease (increase) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r162", "r169" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodEndLabel": "Outstanding, number of warrants (in shares)", "periodStartLabel": "Outstanding, number of warrants (in shares)", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r121", "r122", "r123", "r129", "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r59", "r60", "r224" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r11", "r246" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock $0.001 par value: 200,000,000 shares authorized; 47,879,708 and 47,874,708 shares issued and outstanding at March 31, 2022, and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r35" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r8" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Security deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r47", "r116" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-1-description-of-business-and-basis-of-presentation", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-3-intellectual-property", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-5-related-party-transactions", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-7-significant-events-", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r34", "r64", "r65", "r66", "r67", "r68", "r73", "r74", "r76", "r77", "r78", "r79", "r80", "r225", "r226", "r268", "r277" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share\u2014basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r29", "r30", "r31", "r59", "r60", "r61", "r63", "r69", "r71", "r81", "r109", "r159", "r161", "r205", "r206", "r207", "r215", "r216", "r224", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "us-gaap_ExtinguishmentOfDebtAmount", "terseLabel": "Extinguishment of Debt, Amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r227", "r228" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "terseLabel": "Finite-Lived Intangible Assets, Period Increase (Decrease), Total" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r37" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r47", "r115", "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r114", "r119" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r46" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r46" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r46" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r46" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-3-intellectual-property" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r53", "r112", "r259", "r260", "r261", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r110", "r111" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intellectual property, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r39", "r91" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "us-gaap_LegalFees", "terseLabel": "Legal Fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r16", "r55", "r108", "r229", "r246", "r265", "r273" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r21", "r55", "r108", "r130", "r131", "r132", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r219", "r220", "r221", "r229", "r244", "r245", "r246" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r43" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r43" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided (used) by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r43", "r45", "r48" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r27", "r28", "r31", "r33", "r48", "r55", "r62", "r64", "r65", "r66", "r67", "r70", "r71", "r75", "r92", "r94", "r96", "r99", "r101", "r108", "r130", "r131", "r132", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r226", "r229", "r267", "r276" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r92", "r94", "r96", "r99", "r101" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-1-description-of-business-and-basis-of-presentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other assets:" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r8" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "us-gaap_OtherAssetsNoncurrent", "totalLabel": "Total other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "us-gaap_OtherCommitment", "terseLabel": "Other Commitment, Total" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r38", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "us-gaap_OtherExpenses", "terseLabel": "Other Expenses, Total" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r20", "r246" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities", "terseLabel": "Payment for Contingent Consideration Liability, Operating Activities" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "us-gaap_PaymentsForRoyalties", "terseLabel": "Payments for Royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r40" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "us-gaap_PaymentsToAcquireIntangibleAssets", "negatedLabel": "Additions to intellectual property", "terseLabel": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r40" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r193", "r194", "r197", "r198", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r193", "r194", "r197", "r198", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r10", "r144" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r10", "r144" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r10", "r246" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r41" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuances of stock", "terseLabel": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r117", "r246", "r270", "r274" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r117", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r239", "r240", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-5-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r212", "r258", "r291" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r13", "r161", "r246", "r272", "r284", "r285" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r59", "r60", "r61", "r63", "r69", "r71", "r109", "r205", "r206", "r207", "r215", "r216", "r224", "r281", "r283" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r32", "r55", "r89", "r90", "r93", "r97", "r98", "r102", "r103", "r104", "r108", "r130", "r131", "r132", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r229", "r269" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r174", "r189", "r192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r162", "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r46" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "verboseLabel": "Share based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free rate:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, number of shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "negatedLabel": "Options expired (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Options expired, weighted average exercise price (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted, number of shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, number of shares (in shares)", "periodStartLabel": "Outstanding, number of shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest, number of shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r193", "r194", "r197", "r198", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Options exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Options granted, weighted average exercise price (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r173", "r195", "r196", "r197", "r198", "r201", "r208", "r211" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years): (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r52", "r58" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r23", "r29", "r30", "r31", "r59", "r60", "r61", "r63", "r69", "r71", "r81", "r109", "r159", "r161", "r205", "r206", "r207", "r215", "r216", "r224", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited", "http://www.genprex.com/20220331/role/statement-note-1-description-of-business-and-basis-of-presentation", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-3-intellectual-property", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-tables", "http://www.genprex.com/20220331/role/statement-note-5-related-party-transactions", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.genprex.com/20220331/role/statement-note-7-significant-events-", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual", "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r59", "r60", "r61", "r81", "r262" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited", "http://www.genprex.com/20220331/role/statement-note-1-description-of-business-and-basis-of-presentation", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.genprex.com/20220331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.genprex.com/20220331/role/statement-note-3-intellectual-property", "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-assumptions-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details", "http://www.genprex.com/20220331/role/statement-note-4-equity-tables", "http://www.genprex.com/20220331/role/statement-note-5-related-party-transactions", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.genprex.com/20220331/role/statement-note-7-significant-events-", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual", "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of stock for services (in shares)", "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r10", "r11", "r159", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of stock for cash (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r10", "r11", "r159", "r161", "r180" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "negatedLabel": "Options exercised, number of shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual", "http://www.genprex.com/20220331/role/statement-note-4-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of stock for services", "terseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r10", "r11", "r159", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of stock for cash" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r23", "r159", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised", "terseLabel": "Stock Issued During Period, Value, Stock Options Exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r11", "r14", "r15", "r55", "r107", "r108", "r229", "r246" ], "calculation": { "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.genprex.com/20220331/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r54", "r145", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r161", "r163", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r237", "r248" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r237", "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r237", "r248" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events", "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r247", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-8-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies", "http://www.genprex.com/20220331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r82", "r83", "r84", "r85", "r86", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-note-4-equity", "http://www.genprex.com/20220331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r73", "r78" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of common shares\u2014 basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.genprex.com/20220331/role/statement-condensed-statements-of-operations-unaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r292": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r293": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r294": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r295": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r296": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r297": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r298": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" } }, "version": "2.1" } ZIP 41 0001437749-22-012372-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-012372-xbrl.zip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�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end